BioTOP-Report 2014 - Berlin Business Location Center

Transcription

BioTOP-Report
2014
Biotech and Pharma in Berlin-Brandenburg
BioTOPics 47 | May 2014
BioTOP-Report 2014
Content
Editorial
The German Capital Region – Biotechnology and Life Sciences are Ready for the Future
3
Biotechnology
The Capital Region – New Jobs and New Companies
4
Pharma
Attractive Location
14
Glycoscience
Glyco Research for Innovations in Health Industry
18
Bioelectronics
The Joint Lab Bioelectronics – A New Platform for the Integration of Microelectronics into Life Sciences
20
Business Location
Excellent Services for Berlin-Brandenburg
24
Spotlight on European Business and Internationalization
The Enterprise Europe Network Berlin-Brandenburg
26
Biotech Parks
The BioCampus Network Berlin-Brandenburg
34
Addresses39
Publisher: Berlin Partner für Wirtschaft und Technologie GmbH · BioTOP Berlin-Brandenburg
Fasanenstraße 85 · 10623 Berlin · Germany · Phone +49 30 318622–0 · Fax +49 30 318622–22 · [email protected] · www.healthcapital.de
Editor: Volker Erb
Design & Production: webersupiran.berlin
Translation: Kate Abbott · Berlin
Photos/Figures: BioTOP or authors and:
Page 14 Paulus Rusyanto/dreamstime.com, Sean Pavone/dreamstime.com Page 21 Warenemy/dreamstime.com, Collpicto/dreamstime.com
Page 27 adimas/Fotolia (Profile Alacris), Noah Clayton/co.don (Profile co.don) Page 30 Werner Popp (Profile organobalance).
BioTOP-Report 2014
Editorial
The German Capital Region – Biotechnology and
Life Sciences are Ready for the Future
Berlin-Brandenburg is an extremely attractive location for research and its translation into industrial applications.
The establishment of the Berlin Institute of Health, successful spin-offs and inward investment show that the German capital region provides top conditions for the healthcare industry. Berlin is the start-up capital of Germany!
With its new “Healthcare Industries” master plan, the capital region is setting the course for the sector’s development until 2018.
Basic research, innovation, spin-offs and application – in the future, these will remain the four pillars that determine the successful implementation of the cluster strategy in Berlin-Brandenburg.
Biotechnology/pharmaceuticals, medical technology and the
healthcare industries are the focal areas. In the coming years,
biotechnology/pharmaceuticals development will feature:
The creation of new translation platforms in basic research,
clinical research and industrial biotechnology
Max Planck and Fraunhofer Research, as well as the Helmholtz
and Leibnitz Institutes, are drivers of technology transfer and pioneers of innovative technologies and products.
Concentration on therapy development through new system
medicine strategies
The Max Delbrück Center for Molecular Medicine and Charité –
Universitätsmedizin Berlin are the umbrella for the new flagship of
German biomedicine.
In diagnostics, focus on the development of companion diagnostics
Laboratory medicine, applied research, SMEs and the pharmaceuticals industry are pooling their activities for therapy optimization in personalized medicine.
Development of new growth fields in the life sciences with interdisciplinary technologies
Cross innovation at the interface of microsystems technology, microelectronics, photonics and surface engineering and thin films
open up completely new opportunities for analytics, automation
and hardware development and along with this, for growth, value
creation and cost reduction.
Value chain expansion via inward investment and industrial
location expansion
With more than 200 biotechnology companies, over 30 research
institutions and over 130 clinics and hospitals, Berlin-Brandenburg is already a European hot spot for the life sciences. Growth
in expertise, players and investment will reinforce the capital region’s leading position in the international markets.
This new edition of the BioTOP Report provides you with an exciting, informative overview of the development in the capital region’s industries. With themes such as glyco-engineering technology and bioelectronics, it underscores internationally outstanding
activities. We wish you reading pleasure and invite you to commit
to Berlin-Brandenburg as a place to develop your business.
Reach out and contact us!
In regenerative medicine, concentration on the development of
new cell therapies
The Berlin-Brandenburg Center for Regenerative Therapies
(BCRT), biotechnology SMEs and pharmaceuticals partners in
the international Regenerative Medicine Coalition are part of a
high-performance product development network.
Focus on the sustainable use of biological resources for medical applications in industrial biotechnology
The Leibniz Institute for Agricultural Engineering, university-related
research and biotechnology SMEs are successfully implementing
the federal government’s bioeconomics strategy and contributing
to the strength of the healthcare industries.
Prof. Dr. Peter Seeberger
Expert Circle Spokesman
“Biotech/Pharma“
Dr. Günter Peine
Head of
BioTOP Berlin-Brandenburg
3
BioTOP-Report Biotechnology
Biotechnology
The Capital Region – New Jobs and New Companies
The growth trend of recent years continues in 2013. Employee numbers have grown by 5.6 % (last year, 6.5 %).
Currently, 232 companies employ 4,586 people. The constant momentum is accompanied by many newly founded
businesses.
kk According to the latest BioTOP survey, 232 biotechnology
companies are active in the Berlin-Brandenburg region. This
means the company base has expanded by a total of 10
companies against last year.
kk A total of 14 companies have stopped doing business in the
region, either shutting down completely or relocating.
kk The addition of 24 companies more than compensated for
this loss. Of the new companies, we count 6 additions due
to inward investment and new registration and – particularly
notable – 18 start-ups.
kk The current base of 232 companies has created 352 new jobs.
This translates into a growth rate of over 8 percent.
kk After subtracting the 114 jobs lost due to business shut-downs,
the sector in the region gained a total of 273 jobs, adding up
to regional employment growth of 5.6 % in the sector.
alone – a figure to note. This speaks volumes in favor of the location’s general conditions and the commitment of the many players
involved and their start-up-related activities. And above all, underscores the courage of the many company founders who are
seeking their fortune in this highly sophisticated sector.
Smaller companies dominate the region’s business landscape:
139 companies in the sector have less than 10 employees. Only
13% of the total jobs are located in these companies, however.
Over 53% of the sector’s employees in the region work for the 19
companies with more than 50 employees.
The majority of these companies (88%) focus on the areas of new
therapeutic agents, diagnostic products and biopharmaceuticals
services; followed by 19% in the agriculture/food sectors and 13%
in the industrial biotechnology sector (multiple mentions).
For many years, biotechnology region Berlin-Brandenburg has
been on a steady growth course. One of the sector’s leading regions in Germany and Europe, it hosted 18 start-ups last year
The start-ups still have little effect on the job market. At their
launch, none of these companies had more than 10 employees.
JANUARY 2013
JULY 13
Epigenomics AG hands in fourth module at FDA completes application for
approval as planned +++ co.don® AG applied for approval of joint cartilage
product chondrosphere® in the EU +++ Shire discovered the Munich-based RNA
specialist Ethris for itself. In cooperation the two companies want to find therapies
for rare diseases
Berlin-Brandenburg Healthcare Industries cluster HealthCapital launches new
website: www.healthcapital.de +++ Caprotec expands alliance with Bayer +++
EZAG AG in participation via subsidiary OctreoPharm Sciences GmbH +++ caprotec bioanalytics GmbH and Bayer CropScience enter into second research
collaboration +++ NOXXON Pharma completes patient recruitment for phase IIa
study in diabetic nephropathy +++ Romer Labs® and the Institute for Product
Quality (ifp) launch new AgraQuant® F.A.S.T.
FEBRUARY 2013
Epigenomics receives notice about grant of priority review status and acceptance of the hand-in of the PMA application for Epi proColon® from the FDA +++
Innovation forum “Biopolymers and Bio-based Plastics” in Schwarzheide
MARCH 2013
BIOTECON Diagnostics GmbH extends its robot segment +++ Epigenomics AG
collects 5,0 million Euros through capital increase +++ New research collective
INNO-TRACE develops innovative contrast agents for tumour imaging
APRIL 2013
Europe's largest clinical laboratory at Campus Virchow-Klinikum: Labor Berlin
inaugurates new site
MAY 2013
Bayer HealthCare presents new incubator model for biotech start-ups in Berlin
JUNE 2013
Alacris Theranostics GmbH announces Illumina CSPro certificate for next generation sequencing +++ Humedics co-founder Martin Stockmann receives VonLangenbeck Prize for development of LiMAx test
4
AUGUST 13
Bayer HealthCare concludes partnership and license agreement with Compugen Ltd. for the research, development and marketing of antibody-based drugs
for cancer immunotherapy. +++ caprotec bioanalytics GmbH and Syngenta International AG announce research collaboration +++ Epigenomics AG agreement
with YA Global Master SPV Ltd. brings funding of up to €5 million
SEPTEMBER 13
Eckert & Ziegler BEBIG s.a. takes over prostate cancer implantation business of
American company Biocompatibles Inc. for $5 million +++ Myelo Therapeutics
GmbH successfully completes funding round for the development of adjuvant
cancer therapy
OCTOBER 13
Epigenomics and Polymedco sign commercialization agreement for Epi proColon® for the North American market +++ Sugar is life: GlycoUniverse successfully
launched in Campus Buch +++ Cell Medica, a leading company in the T-cell
BioTOPics 47 | 6. Juni 2014 (3:02)
Dr. Matthias Schroff
CEO MOLOGEN AG
Key milestones achieved
MOLOGEN completed a successful fiscal year 2013 with three
different product candidates in clinical development for the first
time. The final evaluations for the completed clinical trials of
MGN1703 and MGN1601 provided very positive data, and with
MGN1404 (a product that combats malignant melanoma), the
company launched the clinical development phase of another
product candidate within the framework of a partnership, contributing to an expansion of its pipeline. For its most advanced product candidate, the cancer immunotherapy MGN1703, MOLOGEN
was also able to present very positive clinical data from the final
evaluation of a phase II trial in colorectal cancer (IMPACT study)
in 2013. For the most part, the preparations for a phase III pivotal
study in this indication were completed in the course of the last
fiscal year.
Glycotope specializes in the glycosylation of proteins. Glycotope
has a broad portfolio of drugs in clinical development, including
the new cancer drugs, PankoMab-GEX™ and CetuGEX™, both
in phase IIb trials. PankoMab-GEX™ is the first fully glycosylated
and glyco-optimized human antibody for a novel tumor-specific
carbohydrate-protein mixed epitope (TA-MUC1) abundantly present in a larger set of tumor indications, metastases and cancer
therapy field, opens a central European production facility in Berlin-Buch +++
ProBioGen upholds strong patent position in viral vaccine manufacturing field
NOVEMBER 13
Glycotopes Fully Human and Glycooptimized Recombinant FSH-GEX exhibits
superior activity and excellent tolerability in phase II clinical trial for in vitro
fertilization +++ The methylated SHOX2 biomarker from Epigenomics shows
promising results for therapy-related monitoring of lung cancer patients +++
SCIENION´s sciFLEXARRAYER receives product technology innovation award
from Materials Science Society AVS +++ The NeuroPro Alliance, a joint venture between the Technical University of Applied Sciences Wildau, nanoPET
Pharma GmbH and AudioCure Pharma GmbH, receives research award.
DECEMBER 13
OMEICOS Therapeutics: new drug for atrial fibrillation in model systems tests
positively +++ Contichrom® systems from KNAUER receive Berlin-Brandenburg Innovation Award +++ ProBioGen announces expansion of commercial
licenses with emergent biosolutions for AGE1.CR® viral vaccine manufacturing
production platform
We are well aware that our company’s success is also due to
the conditions that Berlin and the capital region offer. Whether research collaboration (FU Berlin) or clinical studies with
Charité Universitätsmedizin and its departments – we benefit
from the close scientific network. The availability of qualified
personell is also a key advantage, which surely ties into the
high quality of life in Berlin. Berlin is a city for conferences
and conventions and many of our sector associations have
their headquarters here. This is another reason why Berlin is
an excellent location for medical biotechnology. As a research
company, we appreciate the fact that Berlin is one of the
world's leading regions and innovative locations in the field
of life sciences.
stem cells. Additional Glycotope products include TrasGEX™,
which has successfully completed its phase I/IIa trial and the improved fertility hormone FSH-GEX™, which is expected to begin
two phase III clinical trials in 2014.
Biopharmaceuticals company NOXXON Pharma is a pioneer in
the development of a new class of proprietary therapeutic agents
called “Spiegelmers,” which are chemically synthesized L-ste-
FEBRUARY 14
The Swedish-German company Amal Therapeutics SA has acquired investors
for a seed financing round +++ mivenion GmbH receives FDA approval for
Xiralite® Fluorescence Imaging System X4 for microcirculation visualization +++
€15 million for Mologen
MARCH 14
Glycotope GmbH raises €55 million +++ FDA Advisory Committee Provides
Recommendations for Epigenomics' Colorectal Cancer Screening Blood Test
APRIL 14
Alacris Theranostics GmbH announces partnership with Walldorfer SAP AG
+++ On May 14, Bayer HealthCare opened its first German CoLaborator in
Berlin-Mitte on the company's premises +++ Bayer Pharma AG participates
in the High-Tech Startup Fund II +++ International pharmaceutical company
Takeda extends production facility in Oranienburg
JANUARY 14
Improved diagnostics for sepsis-associated liver dysfunction with LiMAx test
from Humedics GmbH +++ Epigenomics starts trading on US OTCQX market +++ Cell Medica announces European Union orphan drug designation for
Cytovir ADV +++ ward-winning Ostendum Lab-on-a-Chip nanodevices are produced with SCIENION's sciFLEXARRAYER SX
5
reoisomer RNA aptamers and a non-immunogenic alternative
to antibodies. NOXXON is approaching the completion of multiple proof-of-concept studies with a diversified portfolio of clinical-stage Spiegelmer® therapeutic agents exhibiting high safety
and tolerability, and promising signs of efficacy. Emapticap pegol
(NOX-E36), an anti-CCL2/MCP-1 Spiegelmer®, is currently in a
phase IIa study in patients with diabetic nephropathy. Olaptesed
pegol (NOX-A12), an anti-CXCL12/SDF-1 Spiegelmer®, is currently in phase IIa studies in two hematological cancers: multiple
myeloma and chronic lymphocytic leukemia. Lexaptepid pegol
(NOX-H94), an anti-hepcidin Spiegelmer®, has shown efficacy in
a subset of anemic cancer patients with functional iron deficiency
in a pilot study where the pharmacodynamic parameters of iron
metabolism and erythropoiesis were positively influenced and
hemoglobin levels increased following lexaptepid mono-therapy.
The product will also be evaluated in a phase IIa study in dialysis
patients with ESA-hyporesponsive anemia.
2.442
Number of Employees According to Company Size
2.500
2.400
2.300
2.200
2.100
2.000
1.900
1.800
1.542
1.700
1.500
1.400
1.300
1.200
1.100
1.000
Number of employees
1.600
900
800
602
700
600
500
400
300
200
100
0
'04 '05 '06 '07 '08 '09 '10 '11 '12 '13
139 companies 1-10 employees
'04 '05 '06 '07 '08 '09 '10 '11 '12 '13
74 companies 11-50 employees
'04 '05 '06 '07 '08 '09 '10 '11 '12 '13
19 companies > 51 employees
In comparison to the previous year, the average number of employees per company decreased by 9,2 % in the 1-10 category
and increased 15,9 % in the 11-50 category. The average number of employees in the category > 50 employees increased by 3,7 %.
(Source: Own survey, BioTOP database, 232 companies questioned, February 2014)
6
Epigenomics, a molecular diagnostics company in the process
of developing and commercializing a pipeline of proprietary
products for the screening and diagnosis of cancer, announced
the outcome of a meeting of the Molecular and Clinical Genetics
Panel of the FDA’s Medical Devices Advisory Committee held in
conjunction with its premarket approval for its blood-based colorectal cancer screening test Epi proColon®. The members of the
Medical Devices Advisory Committee voted favorably, determining that the benefits of Epi proColon® do outweigh the risks for use
in patients who meet the criteria.
Caprotec bioanalytics and Syngenta International AG announced
a joint research agreement in which Syngenta will gain access
to caprotec’s proprietary capture compound mass spectrome-
Employees in Biotech SMEs
4.586
5.000
4.500
4.000
3.000
2.500
2.000
Number of employees
3.500
try technology. The companies will work together to profile the
interactions of one of Syngenta’s novel active compounds with
the proteome in its relevant plant biological system. caprotec’s
platform enables the unbiased evaluation of the interactions of
small molecules with protein mixtures in a targeted and directed
manner, which facilitates the identification and elucidation of tractable targets and accelerates the development of promising leads.
Cell Medica announced that the European Medicines Agency
(EMA) Committee for Orphan Medicinal Products has issued a
positive opinion on an application for orphan designation of a
novel T cell immunotherapy under development by the company.
The cell therapy Cytovir ADV targets the treatment of adenovirus
infections in patients following allogeneic hematopoietic stem cell
(bone marrow) transplant. It is comprised of adenovirus-specific T
cells derived from allogeneic donor leukocytes, expanded ex vivo.
co.don is one of the world’s leading specialists in the cultivation
of cells for the joint-preserving treatment of articular cartilage and
intervertebral disk defects. Using the company’s patented therapeutic products, doctors are able to avoid joint and intervertebral
disk prostheses in many cases. An increasing number of orthopedists, orthopedic surgeons and neurosurgeons are relying on this
regenerative therapeutic procedure. This minimally invasive method for articular cartilage regeneration has been successful with
approx. 6,000 patients in Germany. Experts estimate the overall
European market to have a potential annual worth of approx. €1.2
billion. With its current infusion of capital, co.don is paving the
way for the EU-wide approval of its biological therapeutic co.don
chondrotransplant® DISC – an autologous method for treating intervertebral disk damage.
1.500
1.000
500
0
'04
'05
'06
'07
'08
'09
'10
'11
'12
'13
Employment rose to 4.586 in 2013. This is a growth of 5,6 % in
comparison to the previous year. The number of companies went
up to 232, reflecting the arrival of 24 companies (18 start-ups)
and 14 departures. (Source: Internal survey, BioTOP database,
232 companies questioned, February 2014)
MetrioPharm was able to complete the regulatory pre-clinical
study package. The most important outcome was MP1032’s
superior safety profile as confirmed by the results from the various regulatory pharmacology and toxicology studies conducted
throughout the past year. The results of these tests surpassed
all ambitious expectations. Repeated daily administration of up
to 150(!) times the normal therapeutic dose for 28 consecutive
days did not cause any side-effects or adverse events whatsoever.
A clean safety profile is a highly valuable asset for a new drug.
With the impeccable animal safety data obtained for MP1032 an
important foundation for entering clinical Phase I trials in 2014
was laid. For the first time, MP1032 can now be tested directly in
humans.
7
ProBioGen is an internationally operating technology provider and contract development and manufacturing organization
(CDMO) with almost 20 years of experience in cell culture, process development and GMP manufacturing. A competent and
reliable CDMO partner, ProBioGen offers customized solutions
for even the most challenging development and manufacturing
requirements. ProBioGen has signed its latest GlymaxX® ADCC
technology deal with a top-10 pharmaceuticals company for a
therapeutic antibody platform.
early-stage area again in 2013. Subsidies from the states of Berlin and Brandenburg, which contributed project-related funding
volumes of 42 Mio. Euro to life sciences companies alone, supplemented private funding. Investment helps not only the companies
involved, but is also relevant for the development of the overall
biotechnology region, generating useful growth effects above and
beyond its benefits to individual companies.
Conclusion
Investment in the Region
In recent months, these companies have acquired financing of
almost €100 million. Glycotope GmbH has led the field with a
new financing round of €55 million. Investors have supplied the
company with €130 million in the past few years. One of the largest in Europe, the latest round of financing has attracted international attention. It will be exciting to see how Glycotope’s future develops. The listed companies have also obtained a new
infusion of money. Mologen and Epigenomics have been able to
financially safeguard their next steps with new capital increases,
for example. High-Tech Gründerfonds (HTGF) and IBB Beteiligungsgesellschaft, one of the most active venture capital financiers
in Germany, were among the most responsive financiers in the
Dr. Karen Uhlmann
COO/Co-CEO Omeicos Therapeutics GmbH
Dr. Robert Fischer
CSO/Co-CEO Omeicos Therapeutics GmbH
The Berlin-Brandenburg biotechnology region has enjoyed a constant growth trend for years. The companies in the sector have
again proven their competitiveness in 2013/2014. After many years
of developing products and conducting the studies required by
the certifying authorities, the near future will show whether the
investments have paid off. Most of the biopharmaceutical companies are doing so well that is safe to be optimistic, although the
risk remains high. The region’s pool of highly specialized service
providers is only one of the factors upon which this excellent economic development is based. The companies in the sector grow
organically and are typically less dependent on external investors.
They important sector delivers constant, sustainable growth for
the Berlin-Brandenburg region.
Relatively strong fluctuation is typical of the still-young biotechnology sector. Established companies go and new ones come to
take their place. The high number of start-ups, which ultimately
compensate for failed business ventures, is another reason for
optimism. To ensure the successful development of these young
companies, private investors must actively participate in early-stage financing again.
OMEICOS Therapeutics is working on a new drug for the treatment of atrial fibrillation, and would like to implement the clinical development by the end of 2016. The demand for a new atrial fibrillation treatment is high – and with it, its commercial potential. All of the
medicines available now to the majority of patients have a limited effect, and some of them go hand in hand with highly problematic
side effects. Working with their partners at the Texas Southwestern Medical Center, scientists at the Max Delbrück Center for Molecular
Medicine (MDC) Berlin-Buch have identified a metabolism product of the Omega 3 fatty acid with an anti-arrhythmic effect. Based on
this product, they have synthesized drug candidate OMT-33. The fact that the active ingredient can be further developed for commercial use as part of a start-up is due to the very good general conditions existing before the company was even established. OMEICOS
received its initial financial support from the MDC PreGO-Bio funds and Helmholtz Enterprise, the spin-off support project of the
Helmholtz Association. The company received seed financing through a High-Tech Gründerfonds participation and ProFIt funding
from the state of Berlin, which is co-funded with capital from the European Fund for Regional Development (EFRE). With its BioTech
Park, Campus Berlin-Buch provides the ideal framework conditions and an outstanding infrastructure for our product development
phase. Of course the direct proximity to MDC is essential to our success. OMEICOS and MDC will continue to work in close partnership. And our cooperation with the Campus' BBB Management GmbH also makes the location very attractive for us.
8
vfa bio represents the biotech interests within the German Association of
Research-Based Pharmaceutical Companies (vfa). vfa campaigns for the
interests of 45 worldwide leading pharmaceutical companies in the fields
of health, research and economy.
vfa bio seeks to exploit the therapeutic and economic potential of biotechnology to make Germany the leading biotech location in Europe.
Medical biotechnology is vfa bio’s topic. We primarily deal with:
▪▪ Medical progress provided by biopharmaceuticals benefit for patients, physicians and society as a whole
▪▪ Access to biopharmaceuticals for patients
▪▪ Business location Germany and regulatory and economic framework
for research, development and production of biopharmaceutical
▪▪ Orphan medicinal products (medicines for rare diseases)
▪▪ Advanced therapies such as gene and cell therapy and tissue
engineering products
Bild: © vfa / Martin Joppen
▪▪ Biosimilars
Till Erdmann
Managing Director Myelo Therapeutics GmbH
Dirk Pleimes
Managing Director and Chief Medical Officer
Myelo Therapeutics GmbH
But they will only do so if the general conditions for venture capital
are significantly improved. The political decision makers seem to
agree on this objective – now all they have to do is adopt relevant
new laws.
The Start-Up Capital is Booming
For many years, the Berlin-Brandenburg region has been generating international headlines as the start-up capital of Germany.
Hardly a week goes by without a new start-up being founded, a
major financing round being concluded or a major corporation
committing to act as an accelerator or incubator. The region is
booming; it’s an international hot spot. However, this has more to
do with IT and web-based applications start-ups.
We are a young pharmaceutical company that develops new
therapies in fields of application with high medical needs. With
a clear strategy for developing our innovative active ingredient
Myelo001 for treating chemotherapy-induced neutropenia, we
have successfully obtained the support of a series of strategic
investors, including IBB Beteiligungsgesellschaft, Eckert Life
Science Accelerator (ELSA) and Valenta Pharmaceuticals.
The German capital region provides a high concentration of
science and research, clinics and business, as well as a high
quality of life. It is predestined to be a location for pharmaceutical companies. The technology parks and networks that
are part of the Healthcare Industries cluster represent an outstanding infrastructure for translating the latest scientific findings into innovative products.
Market Segments of Companies
204
88%
210
200
190
180
170
160
150
130
120
110
100
90
80
Number of companies
140
70
60
45
19%
50
31
40
14 %
30
20
10
0
'04 '05 '06 '07 '08 '09 '10 '11 '12 '13
Agriculture/Food
'04 '05 '06 '07 '08 '09 '10 '11 '12 '13
White Biotechnology /Environmental Biotechnology
'04 '05 '06 '07 '08 '09 '10 '11 '12 '13
Biomedicine
Most companies focus on biomedicine. A total of 88 % of companies, focus primarily on development in the areas of new diagnostics, drug development
and associated services or technologies. 13 % of the companies are active in the agriculture / food sector, white biotechnology / environmental
biotechnology amounts to 19 % of all entries. (Source: Internal survey, BioTOP database, responses from 232 companies, multiple entries, February 2014)
10
A AT
GGA
AT C
G TA
TA A
CCA
AG G
GTT
TCC
ACA
GCC
TGA
GCC
G AT
AT C
G TA
AG G
GA A
CAC
CGA
GCC
CAA
AGC
ACC
TA A
AGT
GTT
T G A CAC ACG T TC GCC
C C A T C A C G A TA A A A C
GA A ACC GA A TCA GCC
T T G CA A GGC CAC CAG
AC T GGA ACA AGA TCC
STudieS & ConSulTinG
T T C G TA T T A A C T A G A
ConferenCeS AAG G A G
CTC CTG GCG GTG TCA
BookST C T C G C C A TA A
ACG G A A A C G G G T G A C
T V & VideoA C T C C G C A
TA G G C T C A A A AC G C A
CorporATe puBliShinG
C A G C T T A C C AGA T G C
inTerneT C T C C G C A C G
G T T T C C A C A GCC T G A
MAGAzineSG A T T C G T C
T C A ACC CA A GGA G T T
e V enT MAnAGeMenT T A
A AC GCC CAG TCC AT T
CAC GCT G T T CCC GGA
G G C AAA G C A C A T C C A
GGC GCA T G T T GA CAC
G C T AGA CA A ACA T C T
G T T C T C A AG GA A TGA
A C T A C G T C C T G C AT G
BIOCOM AG | Lützowstraße 33–36 | 10785 Berlin | Germany
www.biocom.de | Tel. +49 (0)30 264921-0 | Fax +49 (0)30 264921-11
G AT A A G G A A G T T AT G G A A
GGA C A A T TA C C C G AT T G G
AGT CA A GA A G C T T TC GAC
TA G C A C A C G T G C G G A A C G
AAA G C T T A T T G G A A G T G C
G C A TA C C A A T G C AT G C A C
G AT C AT T C T A A C C C T T A T
AT C C C C T T G A C C GGC C G G
A AT C A G T G A C G A C C G T G T
C G T T G G C T T A A A G C T TA G
G G G A AT C C A A C C GAC A G A
C A T T T G C G A G C T A G A ACG
T G T G C C G AT C A A G A A T G C
T T T G G A GA A C T A A C A T C T
A AG AT C T T G G G A G G C A C T
T C C A AT G G A AT C G T A TA A
G C C G A T AT C G TA AG G T G A
C T C A G T ACG T C A TA G C A A
G TA C TA C T G C G C G A A C T T
GCG TCG ACG CAC CA A T G C
AGA GAG TCA TA A GAC GCA
T G C A C A G C C AG G A C T C T T
AGA GA A TGG GAC ACG TGC
A AT C A G C C T G A T TA G C A C
W e C r e AT e k n o W l e d G e !
CGA T G T GCC T T G ACC TCG
T T G CGA T T G GGA AGA A A A
CCT
AAA
TGC
ACA
CCG
GGA
AGC
TTT
ACA
GCC
AT T
TA A
A AG
AGA
GAG
CCA
CAA
ACT
ACG
ACC
GCA
TGC
CAC
CAG
TGG
ACG
CTC
Does this status relate at all to start-ups in the life sciences? At first
glance, perhaps not. But take a closer look: The large number of
players (founders, investors and incubators), the university support programs and many start-up competitions, and the range of
various activities create a start-up-compatible atmosphere, which
has a positive impact on the start-up scene in the life sciences.
Putting it simply, the spillover effect is high.
There have not been as many life sciences start-ups in years as
there were in the last half of fiscal year 2013/2014. And the striking thing about them is that some of the new companies are focusing on new drug development. Here are a few examples of recent
start-ups and their concepts:
OMEICOS Therapeutics is a spin-off of the Max Delbrück Center for Molecular Medicine. It develops synthetic compounds with
innovative modes of action for the treatment of various human
diseases. The company is working on a new drug for the treatment of atrial fibrillation, the most common type of human cardiac arrhythmia. Myelo Therapeutics has developed a drug for
the prophylactic treatment of post-chemotherapy patients whose
blood contains too few white blood cells (neutropenia) or platelets
(thrombocytopenia). Venture capital investors IBB Beteiligungsgesellschaft with their VC Fonds Technologie Berlin, Eckert Wagniskapital und Frühphasenfinanzierung and JSC Valenta Pharmaceuticals are in the company’s financing consortium. Amal
Therapeutics, a company with facilities in Geneva and Berlin, is
developing a vaccine consisting of a recombinant protein with a
cell-penetrating peptide acting as a vector. The unique property
of this platform is its ability to trigger a highly integrated, multi-epitopic cellular immune response to cancer cells. DexLeChem, a
TU Berlin spin-off, provides development services to the chemi-
Our Business: Committed to Improving Health
For more than 230 years, Takeda has been serving society
with innovative medicines. Now, with new healthcare solutions
from prevention to care and cure, we are determined to help
even more people enjoy their lives to the fullest. Of our 30,000
employees worldwide, 1,700 are working in Germany to
develop, produce and market a broad range of medicines to
help patients reclaim valuable moments of life from illness.
12
www.takeda.de
Financing and Added Value
Venture Capital
for companies in Berlin
cal-pharmaceutical industries for making production processes
more chiral, meaning to convert substances with spatially complex
designs into water-based processes. The catalyst is not modified
before re-use. With this resource-conserving reaction process
control, customers – drug and fragrance manufacturers – benefit
from more cost-efficient, environmentally friendly production processes. GlycoUniverse is a technology spin-off of the Max Planck
Institute of Colloids and Interfaces. The company specializes in
the automated development and synthetic production of complex
sugars. With GlycoUniverse’s state-of-the-art oligosaccharide
synthesizer GLYCONEER®, the process of synthesizing complex
carbohydrates that formerly took months or years can be completed in a matter of days or even hours.
The high number of start-ups is the result of a critical mass of
players, activities and initiatives in the start-up area, its welldeveloped infrastructure and excellent location factors as
well. These include the seven biotechnology parks that make
affordable laboratories and technical infrastructure available,
and the many scientific institutes that produce highly skilled
specialists. The universities join in with comprehensive spin-off
support programs, some of which are triggered by the federal
government’s “EXIST-Gründungskultur - Die Gründerhochschule”
competition. Pharmaceuticals giant Bayer Healthcare has
also discovered the region’s potential, providing the technical
infrastructure, professional support and expertise of an
established pharmaceuticals company to young companies via
its CoLaborator, opened in May. Another important element is the
many business plan competitions in which founders receive initial
feedback for their business concepts. With 140 events, a network
of over 200 consultants and over 500 business plan submissions
per year, the Berlin-Brandenburg Business Plan Competition is
one of the largest competitions of this type in Germany.
The momentum in the Berlin-Brandenburg region is powerful –
especially at the interface of IT and the life sciences. There are
a variety of names for this new area, including eHealth, itHealth,
dHealth and mHealth. What they all designate is the successful fusion of the two fields, facilitated by web-based applications in the
medical sector. This development is still young, but with its unique
density of IT and life sciences players, the Berlin-Brandenburg
location is particularly suitable for generating new companies.
The first companies have already been founded; take Caterna, an
online school for visual exercises, or NeuroNation, the new digital
brain-jogging platform for example. There are many new companies in this new field, and in XL Health, it even has a financially
strong investor specialized in digital health.
IBB Beteiligungsgesellschaft mbH offers equity financing for high tech companies in Berlin. For our fund
VC Fonds Technologie Berlin (€52m) we are looking
for investment opportunities in the biotechnology and
medical technology sector.
Our investment approach is based on hands-on involvement and active management support for each
portfolio company, delivered by our highly experienced investment team. VC Fonds Technologie Berlin
not only provides capital, but also helps execute the
business plan.
Are you interested? Please do not hesitate to contact us.
IBB Beteiligungsgesellschaft mbH
Mrs. Ute Mercker / Mr. Christian Seegers
Bundesallee 210
10719 Berlin / Germany
Phone: +49 (0)30 2125-3201
www.ibb-bet.de
Selected portfolio companies:
VC Fonds Technologie Berlin was set up as a joint initiative of Investitionsbank
Berlin (IBB) and the State of Berlin. It is co-financed by the European Regional
Development Fund (ERDF).
13
BioTOP-Report Pharma
Pharma
Attractive Location
The capital region has developed into one of Germany’s most important, attractive centers for the medical and
healthcare industries. Based on the significant growth of the pharmaceuticals industry in Berlin, these sectors are
the growth engine of the regional industry. Currently, the sectors employ approx. 10,000 people in the German
capital region. This means that pharmaceuticals companies account for around one in every 10 jobs in the regional
industry – and every 11th employee in the pharmaceuticals sector in German works in Berlin.
ing research locations. The partnership between pharmaceuticals
companies, clinics and hospitals and scientific institutions guarantees ultra modern patient healthcare of a uniquely high quality,
and the innovations of the pharmaceuticals companies are creating and securing the jobs of the future for the region.
The current investment and activities of the local pharmaceuticals sector are proof of Berlin's appeal and bear witness to the
companies' commitment to the capital region. Bayer has paid
billions to conclude the takeover of Norwegian cancer treatment
specialists Algeta. Bayer made the move to strengthen its position
in the tumor medication area. The company is also increasing its
commitment to young, innovative technology companies. In May
2014, it launched the CoLaborator incubator program. An incubator model for biotechnology start-ups, CoLaborator was tested
in San Francisco (Mission Bay) two years ago. In the specially
equipped research building, up to 10 innovative biotechnology
companies can now get to work – thanks to Bayer.
Globally active corporations are located along the Spree River:
Bayer Healthcare, Berlin-Chemie, Pfizer Deutschland, Sanofi
Deutschland and since 2011, Takeda. The capital region is also
home to over 20 medium-sized pharmaceuticals companies, including several world market leaders.
Above all, the sectors benefit from the capital region’s excellent
scientific environment and clinical research landscape, the proximity to decision-makers in the healthcare system and the ready
availability of well-educated skilled specialists. A steadily growing
number of global players and medium-sized companies are setting up business here or moving their corporate headquarters to
Berlin and the capital region, to take advantage of these location
assets. With over 220 companies, Berlin is also a leading global
location in the biotechnology sector and the pharmaceuticals industry has created a close, innovative network with these partners.
The Berlin-Brandenburg region has an outstanding position in several sectors that the experts certify as having a strong growth
outlook due to their excellence in innovation.
The pharmaceuticals sector's innovative excellence pays doubly
for Berlin-Brandenburg, which is also one of the country's lead-
14
Within the next two years, Berlin-Chemie will invest €40 million in
the expansion of its location, continuing to develop its position as
one of the sector's leading employers.
Dr. Rainer Uppenkamp
CEO Berlin-Chemie AG
In Berlin, we find an excellent scientific and commercial environment. This is an important basis for further investments and
the expansion of our location in the south-east of the city. In
addition required extensions are planned, among others a new
building for the quality control, a new staff canteen, an extension of the office capacity for the administrative area and the
resulting infrastructural measures in the form of new roads,
paths and parking facilities for our employees.
You need commitment, focus and
passion to find new ways to fight the
diseases of this world: innovation
is at the heart of it.
Innovation for better health. Our commitment
is to bring to patients around the world quality
medicines for use in diagnosing, combating and
preventing disease. Every day we work against time,
researching new pathways, new molecules, new
technologies – complementing our own capabilities
with exper tise of innovative partners from science
and industry.
www.bayerhealthcare.com
www.bayerpharma.com
The success of this work is evidenced in new
medicinesforareaswithsignificantunmetmedical
need such as oncology, cardiovascular and blood
diseases, as well as gynecology and ophthalmology.
Our aim is a better quality of life for all.
BioTOP-Report Pharma
extreme pain. The special formlulation was designed for targeted
retardation and 24-hour continuous analgesia when taken once a
day. Founded in 2008, the company belongs to a growing group
of German companies headquartered in Berlin.
Alfonso Casal
CEO
PharmaMar GmbH
Our presence in Germany, the European State Member with
the largest population in the EU and strong research capabilities is an important step in our European expansion. From
our offices in Berlin we coordinate our commercial operations
as well as supporting other corporate activities in Germany.
Berlin as Capital city, with important competence centers for
the treatment of cancer and strong international orientation
represents a very good opportunity for the development of our
activities.
The partnership between Sanofi and Charité that began in May
2010 with a focus on the area of stroke research has proven fruitful. The partners have signed an agreement to a second joint
research partnership, this time with a focus on diabetes. The
scientists and clinicians of both parties will also collaborate in a
diabetes alliance in the future. The alliance aims to improve understanding of the medical requirements and approaches to the
disease of diabetes and, in joint projects, to implement them as
therapies and make them available to patients more quickly.
After the acquisition of Nycomed in 2011, Takeda moved its German headquarters to Berlin and took over the Oranienburg-based
production plant. Oranienburg has a long tradition as a location for
pharmaceuticals production. In the past 20 years, the plant there
has expanded continuously. It now has a production capacity of
7.6 billion pills and capsules per year – 98 percent of which are
exported worldwide. The Oranienburg facility is considered one
of the main competence centers within Takeda's global production network. Takeda plans to expand the Oranienburg facility's
production capacity within the next few years.
An important new player, Teva Specialty Medicines, has recently
set up business in Berlin. Newly founded Teva Specialty Medicines is Teva Pharmaceuticals' Original Products division in Berlin.
Its primary area of success is neurology. Teva is the leader in
generics in Germany and an expert in innovative brand business.
At a January 2014 press conference in Berlin, Aristo Pharma presented a new formulation of a proven drug for treating severe and
16
DR. KADE acquired Takeda’s OTC business for the German market in April 2013. With this move, the traditional Berlin company
has added well-known brands to its current OTC portfolio and
made an investment in the future. In conjunction with the expansion of its OTC business, the company has added new employees
in its Berlin and Constance locations.
PharmaMar is a Spanish member of the Zeltia Group, a leader in
the development of anti-tumor drugs of marine origin. PharmaMar
started its activities in Germany in 2007, when the EMA granted
it marketing authorization for Yondelis® in the treatment of soft tissue sarcomas. Two years later, Yondelis® was approved for the
treatment of ovarian cancer. In 2013, the company established
PharmaMar GmbH in Berlin.
These current examples are only an indication of the pharmaceuticals industry activity in Berlin-Brandenburg – but they illustrate
the extent to which the opportunities here are multi-faceted. They
range from close partnerships with regional biotechnology startups and partnerships with science to location expansion and
inward investment. The range of opportunities and the strategic
options they generate make the Berlin-Brandenburg region highly
attractive.
Dr. Hans-Christian Meyer
Site Manager
Takeda Plant Oranienburg
Pharmaceutical development and production has a long tradition in the area of Berlin-Brandenburg. The roots of our production plant in Oranienburg trace back to the 19th century.
Today, our site plays a pivotal role as a competence center for
solid forms such as tablets and capsules within the worldwide
pharmaceutical production network of Takeda. The support
of the Investitionsbank des Landes Brandenburg helps us to
further expand production capabilities, be prepared for future
growth and create new jobs.
We – for the life
Modern research, development and manufacturing
of innovative medicines in Berlin-Adlershof – this is
what BERLIN-CHEMIE stands for. Research and
production are based not only on our experience of
over one hundred years but also on our successful
search for new therapeutic pathways and possibilities. The success we have gained around the world
and the growth of BERLIN-CHEMIE are an endorsement of our high standards.
For more information:
BERLIN-CHEMIE AG · Glienicker Weg 125 · 12489 Berlin
Phone: +49 30 6707-0 · www.berlin-chemie.de
BioTOP-Report Glycoscience
Glycoscience
Glyco Research for Innovations in Health Industry
Alongside genome and proteome research, the study of sugars glycoscience, is increasingly gaining importance.
As our knowledge about the function of sugar structures in a variety of biological processes grows, the areas of
application for glycoscience are also growing and affecting other fields in the Healthcare Industries cluster such as
diagnostics, drug development, regenerative medicine and industrial biotechnology. Sugars can develop complex
structures, glycans, and can be even bound to proteins – in which case they are called glycoproteins. Glycans
are important for a wide variety of biological processes. They control cell-cell communication and the function and
stability of proteins, and play an important role in the immune response. Carbohydrate metabolism malfunctions
are typically associated with neurodegenerative diseases, infections and cancer.
Exploiting high potential for interdisciplinary
technologies
Glycan structures, as molecules expressed due to illness, can
be used as significant diagnostic parameters and can serve as
differentiation markers for regenerative medicine. Glycan-based
molecules can also be used as vaccines e.g. for malaria and HIV.
Glycoscience also contributes to the development of drugs, innovative foods and human-compatible biomaterials. When considering the diverse application fields of glycoscience, it is apparent that the capital region occupies an outstanding position.
Berlin-Brandenburg is a technology leader in the chemical synthesis of glycans, and in glycan analytics it offers internationally significant expertise. We also provide excellent conditions for
applications in the fields with high cross-innovation potential. The
region is a leading international location for research and development in diagnostics and the implementation of clinical studies
and also has highly productive drug and nutrition research. With
the university hospital Charité Universitätsmedizin Berlin globally
acknowledged medical expertise is also present in the region.
growth period in recent years and the acquisition of €55 million
in venture capital, Glycotope now has over 180 employees and
is a world leader in glycobiotechnology. The objective is to turn
Berlin-Brandenburg into a leading international center for glycoscience research and translation for the development of diagnostic and pharmaceutical products, cell-based therapies and new
materials for medical applications by employing an expansion
strategy. We will also be working to intensify the technology transfer based on regional networks and stabilize the communication
between science and industry.
GlycanForum, the international conference that takes place in Berlin every year, presents the current status and outlook for glycoscience in biomedicine. It is organized with the support of the Center
for Molecular Diagnostics and Bioanalysis (ZMDB) and BioTOP
Berlin-Brandenburg. The most important conference in the world
with regard to glycoscience, GlycanForum is an outstanding open
exchange platform for business, industry and users. With a subtheme of "The leading scientists of Asia," the 7th conference in
2013 was focused on the topics of healthcare, material science,
analytics and synthesis.
Establishing a glyco hub in the capital region
Research, whether university-related, independent or clinical,
forms the outstanding scientific basis of the region. The Charité
has been honing its expertise in the fields of glycoanalytics and
glycodesign for many years. The director of the Max Planck Institute of Colloids and Interfaces in Potsdam (MPIKG) and internationally renowned glycoscientist Professor Peter Seeberger
discovered and developed the total synthesis of complex carbohydrates. GlykoUniverse, a spin-off company, will distribute the
completely automated carbohydrate synthesizer. There are other
excellent companies in the region as well. Located in Berlin, Scienion GmbH is distinguished in the field of glycan microarray technology for molecular diagnostics. Glycotope GmbH is specialized
in optimizing sugar structures of glycoproteins and developing
therapeutic antibodies for cancer cells. In the wake of a strong
18
Dr. Véronique Blanchard
Head of Glycoanalytics working group
at the Institute of Laboratory Medicine,
Clinical Chemistry and Pathobiochemistry,
Charité – Universitätsmedizin Berlin
As a location for glycoscience, the capital region is unique in
Europe. You find the entire spectrum here, from basic research
to manufacturing industry, which creates the ideal conditions
for efficiently translating research innovations to industry and
clinics. At Charité, we are researching the potential of glycanbased biomarkers in tumor diagnostics and in bioanalytics for
the quality assurance of stem cell preparation, and developing
a glycan microarray platform for diagnostics.
Corporate Finance Consulting for Life Science Companies
With more than 15 years of experience, Portus
Corporate Finance supports technology focused
companies in all areas of financing. We base our work
on solid know-how, years of experience and reliable
business partners.
Portus Corporate Finance GmbH
Friedrichstr. 81
D-10117 Berlin
Tel
(030) 700 800 900
Fax
(030) 700 800 901
Email
[email protected]
If you are looking for advise and support in the
areas of
• Company and Project Funding
• Company Succession / M&A
• Finance Management / CFO-Services
• Consulting and Coaching
• Establishment of Businesses
please don‘t hesitate to contact us!
www.PortusCo.com
UHY Deutschland AG is a joint venture of long established
auditing and consulting firms with a total of 250 employees
and partners.
As a member of UHY International, a global association of
independent accounting and consulting firms with over
7,600 employees, we can provide audit, accounting, tax
and consulting services in 275 business centres across the
globe.
We offer the following services:
• • Audits of financial and consolidated statements
under the German Commercial Code (HGB) and IFRS
• • Accounting & Reporting
• • Due diligence (financial and tax) and business valuations
• • Consulting services on IPOs
• • Business Advisory
• • Mergers & Acquisitions (M&A)
• • German and international taxation
UHY Deutschland AG has extensive experience in financial
and consulting services for life sciences companies for
many years.
We have offices in Berlin/Bremen/Cologne/Frankfurt/Hamburg/Munich/Stuttgart
For further information please contact Dr. Ulla Peters
UHY Deutschland AG · Wirtschaftsprüfungsgesellschaft · Zimmerstraße 23 · 10969 Berlin
Phone +49 30 226593-0 · Fax +49 30 22679050 · www.uhy-deutschland.de · www.uhy.com
BioTOP-Report Bioelectronics
Bioelectronics
The Joint Lab Bioelectronics –
A New Platform for the Integration of
Microelectronics into Life Sciences
The introduction of new experimental techniques causes a major advantage in the field of biology. Well-known
examples are the invention of optical and electron microscopy, without which the fundamental structures of life as
cells and cell organelles could not have been discovered. The next paradigm shift may very well be triggered by
applying microelectronics – and its developing field of bioelectronics – at its interdisciplinary interface with the life
sciences.
This positive outlook is mainly a result of the phenomenon called
“scaling” in microelectronics: for the last few decades, minimum
feature dimensions have continuously become smaller by a factor of around two every second year. At first glance, this seems
to be a minor development relating to an uninteresting technical
parameter, since we have become accustomed to working with
increasingly powerful computers and to storing higher and higher
data volumes on a single flash memory. For the life sciences, however, scaling is a major advance. It has taken microelectronics or
more accurately, nanoelectronics, to the same structural levels at
which the molecular mechanisms of life operate.
tage of this development and therefore, IHP in Frankfurt (Oder)
and the TU Berlin Institute of Biotechnology have founded Joint
Lab Bioelectronics. This step will intensify the interdisciplinary exchange between the two disciplines and expand biotechnology
students’ knowledge of the basics of microelectronics.
Prof. Dr. Peter Neubauer
Technische Universität Berlin
Institute for Biotechnology
Particularly interesting perspectives arise for biosensorics, in
which semiconductor preparation technology can be applied to
the fabrication of cost-effective diagnostic systems. Bioelectronics is also significant for the process analytical techniques (PAT)
for monitoring, regulating and increasing the efficiency of bioprocesses. The Berlin-Brandenburg region is eager to take advan-
Chair for Bioprocess Engineering
The Joint Lab Bioelectronics aims to advance the field of BioProcess Analytical Technologies by connecting sensor specialists and bioengineers.
JANUARY 2013
JUNE 13
Charité and FU are jointly successful in the competition "EXIST-Gründungskultur
– Die Gründerhochschule" of the German Federal Ministry of Economics and
Technology +++ German Research Foundation extends collaborative research
centre (SBF 650) at Charité – ten million Euros for research on immunological
therapy
BIH officially opened +++ Charité – Universitätsmedizin Berlin once more reaches rank 1 of Focus-ranking "Germany's best hospital"
FEBRUARY 2013
Humboldt research award gets Ivy-League professor Klaas van Wijk to Potsdam
+++ Biopolymers – strong future field with high potential for innovation presents
itself in Schorfheide
MARCH 2013
Hasso-Plattner-Institut speeds up personalised medicine with new data bank
technology +++ Integrative Research Institute for Life Sciences (IRI) founded in
Berlin +++ Paul Ehrlich- and Ludwig Darmstaedter Prize goes to MDC scientist
Dr. James Poulet
APRIL 2013
Charité and Sorbonne found Virchow-Villermé Centre for Public Health +++ EUOPENSCREEN included in the new BMBF-roadmap for large research infrastructures
MAY 2013
New laboratory building of MDC opened – named after physiologist Max Rubner
+++ Stem cell researchers in Germany pool their expertise. They found the German Stem Cell Network (GSCN) on May 7th 2013 +++ Evaluators praise Berlin
Institute of Health (BIH). Enst Theodor Rietschel becomes chairman
20
JULY 2013
Prof. Angelika Eggert receives Einstein professorship and takes over as head of
the Children's Clinic with focal areas of oncology and hematology +++ Scientists from the A*STAR Genome Institute Singapore and the Max Planck Institute
for Molecular Genetics (MPIMG) in Berlin decode the communication network in
human embryonic stem cells +++ Scientists from Charité and the MDC, working
in cooperation with colleagues in Kiel, Boston, Zurich and London, discover a
new gene for hereditary heart failure +++ Scientists working with Peter Seeberger
(MPIKG) in Potsdam-Golm have developed a simple, cheap and reliable test for
Yersinia pestis, the bacteria that caused the plague
AUGUST 2013
1000th protein structure decoded at BESSY II +++ The World Health Summit 2013
in Berlin in August 2013 discussed solutions for global healthcare with regard to
“Research and Innovation.” +++ BPI and vfa present national plans of action for
the quick diagnosis and more effective treatment of rare diseases
SEPTEMBER 2013
Scientists at Charité and MDC discover sugar withdrawal as an innovative cancer
therapy approach +++ Technische Universität Berlin and Leibniz Institute IHP
Frankfurt (Oder) have established Joint Lab Bioelectronics, a laboratory for joint
interdisciplinary research +++ Charité and Harvard sign a cooperation agreement aimed at accelerating clinical translation, primarily in the cell and tissue
technology field +++ Prof. Annette Grüters-Kieslich, Charité Dean, receives the
PD Dr. Mario Birkholz
Head of Joint Lab Bioelectronics
IHP GmbH
Leibniz-Institut für innovative Mikroelektronik
By establishing the IHP and TUB Joint Lab Bioelectronics, we
have created the opportunity for a successful interdisciplinary
partnership. Through it, we will be able to translate the progress made in microelectronics directly into biotechnological
applications and university education.
The Leibniz Institute IHP – Innovations for High Performance
Micro
electronics – in Frankfurt (Oder) is part of the Leibniz
Association and has a long tradition in the area of silicon-based
microelectronics. The IHP has a clean room at its disposal for the
pilot serial production of 200-mm Si wafers in which microchips
are processed at the 0.25 and 0.13 µm structure levels. A family of
SiGe: C-based hetero bipolar transistors for realizing frequencies
in the low 100 GHz range is the core of IHP technology. As part
of IHP’s multi-project wafer services, external customers may use
the technology for the fabrication of application-specific integrated circuits.
highest honor offered by ESPE, the European Society for Paediatric Endocrinology: the Andrea Prader Award +++ New Helmholtz post-graduate school for
researching biomaterials opens
OCTOBER 2013
Fraunhofer researchers receive an international award for ArtCornea®, their
artificial cornea +++ The capital has healthcare in focus: Berlin Health Week
celebrates its launch +++ Sanofi endows two new professorships in the public
health field at Centre Virchow-Villermé, the newly established German-French
research institute, in its Berlin and Paris locations +++ Charité opens the intensive care station of the future
NOVEMBER 2013
NeuroProAllianz receives Technical University of Applied Sciences Wildau
research award Dr. Jean-Yves +++ K. Tano from the University of Toledo arrives
in Berlin after receiving an Alexander von Humboldt fellowship +++ Charité
coordinates the national network of biobanks +++ Immunologist Prof. Klaus
Rajewsky from MDC Berlin awarded the Society for Signal Transduction medal
of honor
DECEMBER 2013
Charité opens pioneering robotics operating room +++ Scientists from Charité
present new approaches toward improving breast cancer therapy as part of
the RESPONSIFY EU research project
JANUARY 2014
Under the leadership of Cornelia Weikert from the German Institute of Human
Nutrition (DIfE), a team of scientists has discovered a new biomarker for heart
The TU Bioprocess Engineering chair conducts research on the
characterization of industrial-scale bioprocesses and methods for
consistent, faster bioprocess development. The chair runs a bioprocess pilot plant with advanced analytical instruments, on-line
instrumentation and an analytical laboratory for comprehensive
metabolomics analysis. Its key instruments are proprietary, scaledown two- and three-compartment bioreactors, which enable the
simulation of large-scale industrial processes in the lab. The characterization of biogas plants, brewery reactors and reactors in
industrial biotechnology with new PAT and model-based process
control for improving their robustness are a major focus. For this
failure in the general population +++ Researchers at MDC Berlin have acquired
new knowledge of the body's regulation of insulin production for insulin resistance, the root of type 2 diabetes +++ The biochemist and protein crystallographer Prof. Oliver Daumke from MDC Berlin-Buch receives European Research
Council funding worth millions +++ BTU Cottbus-Senftenberg strengthens biomaterials research network with Helmholtz Center Geesthacht in Teltow
FEBRUARY 2014
MPIKGPotsdam director Prof. Peter Seeberger and the director of the NII in
New Dehli, India agree to intensify their partnership for researching infectious diseases +++ Researchers at MDC decipher the creation of new forms
of hereditary Alzheimer’s disease and discover new protective mechanisms
+++ Researchers at the Max Planck Institute for Moldcular Plant Physiology in
Potsdam-Golm discover new adapter proteins for the reception of substances
in plant cellss +++ The Berlin Institute of Health (BIG) acquires Thomas Südhof,
Noble Prize for medicine co-awardee, as visiting fellow
MARCH 2014
Two dozen Fraunhofer Society institutes establish the Big Data Alliance +++
MDC receives 3-Tesla MRI scanner for the largest long-term German population study +++ MDC researchers discover the molecular switch for epilepsy
APRIL 2014
Berlin Institute for Health Research launches first research projects +++ HansHilger Ropers awarded with the “EURORDIS Scientific Award 2014” for his
research on rare diseases
21
purpose, new lance- and rope-based mobile sensor and sampling systems that can be directly applied to analyze concentration gradients have been developed.
A robot-based mini pilot plant has also been established for process development in micro-plate and mini-bioreactor cultures.
This highly automated facility focuses on processes with genetically engineered microorganisms. Extensive analyses are automatically performed on tens to hundreds of cultivations in μl
and ml formats. The laboratory pioneered the EnBase® controlled
substrate delivery technology, which is instrumental for consistent
150
T dependence of tsw
in sensoric fluid
for varying cg
switching time tsw (ms)
140
130
30º
100
Joint Lab Bioelectronics’ mission is to introduce new biosensor
technologies. This work focuses on the adaption of the sensor
system to the particular biotech application. The starting point is
the sensor chips developed at IHP, including a fully embedded
microelectromechanical system (MEMS) for affinity assays and a
cell sensor operated via impedance spectroscopy (see Fig. 1).
However, the biochips fabricated in semiconductor fabs require
special packaging before being introduced into bioprocesses
with an emphasis on hermiticity and must be shielded against
corrosion from the liquid bio milieu.
The demand for microsensors for applications in microfluidic
platforms has jumped in recent years. Many applications rely on
polymer devices, because most companies and scientific working groups have almost no access to microelectronic fabrication
techniques. Joint Lab Bioelectronics follows the approach of developing and supplying biotechnological platform modules that
combine equal shares of microelectronic and microfluidic components.
Bioprocess engineering is one promising field of application for
miniaturized sensors. Industrial bioprocess development faces
the challenge of reducing the risks, costs and timeframe of new
product launch. In the pharmaceuticals industry in particular, the
regulatory authorities expect dossiers to be based on knowledge
that derives from careful sensing (PAT). Consequently, future bioprocess development will consist of HT technologies based on
miniaturizing, parallelization, automation and intense monitoring.
120
110
bioprocess development and a key element in this high-throughput (HT) automated industrial reference laboratory.
35º
40º
90
80
glucose concentration cg (mM)
Figure 1. Affinity-viscosimetric microsensor chip with fully embedded
MEMS (X-shaped beams on the left) und calibration curves for glucose
concentration measurements it has taken, Birkholz et al., J. Appl. Phys. 113
(2013) 244904.
Joint Lab Bioelectronics is a perfect match for the Bioprocess
Engineering chair’s HT lab, where platform technologies are developed to comply with the above-mentioned needs. This lab is
Joint Lab Bioelectronics – miniaturized sensors
EnBase®
Robotics
MagReSynTM
DoE
Sensors
Integration
Fed-batched in μl
and mL scale
Automated
cultivation
Automated DSP
and analytics
Experimental
plans, modelling
On-line
data reading
Automated
data evaluation
Figure 2. Steps in consistent, automated bioprocess development based on process analytical technologies, experimental design approaches and the early
consideration of the industrial process by applying the fed-batch mode.
22
able to screen volumes of as little as 200 µl per vessel, in up
to 96 vessels at the same time. Process development and production process characterization take place simultaneously, in up
to 48 miniaturized stirred-tank bioreactors with a working volume
of approx. 10 ml. The cultivation, process analytics and product
recovery processes are automated with the help of a liquid handling system (lab robot). In close collaboration with Joint Lab Bioelectronics, the scientists explore the application and integration
of microsensors for glucose concentration and cell density in HT
systems. The overall process development approach relies on
consistency: experimental planning determines parameter fields,
production systems are investigated under process-related conditions and IT tools handle data. These platform technologies are
currently being applied to specific demonstrator processes. Interested customers can also take advantage of the HT lab’s services.
Last but not least, Joint Lab Bioelectronics aims to teach microelectronics to Biotechnology students, since the job markets of
the the future will demand large numbers of graduates specialized in this field. The “Introduction to Bioelectronics” course was
introduced in 2012 and has been held every summer semester
since then. It was recently included as a mandatory elective
course in the Master of Biotechnology program at TU Berlin.
For the second year in a row, Joint Lab Bioelectronics will organize
a bioelectronics symposium in September 2014, where leading
experts in the field will discuss their recent developments. IHP will
present its biotechnology-relevant technology modules during the
second day of the symposium. We cordially invite interested colleagues from the life sciences and microelectronics to participate
in the symposium.
Achieve innovation,
shape the future
Start shot for young technology companies
High Tech Gruenderfonds is your partner for Seed Stage investing. We
help out young, high potential startups in the early phases of technology
and product development, as well as successful launching. Our assistance
is not limited to our cash investments, instead we strive to add long term
added-value to portfolio companies through our extensive network of
professional and our accredited coaches.
High-Tech Gründerfonds Management GmbH
re
e
twa
enc
Sci nce
Sof ation
e
f
i
e
L
ce
nic
Sci str y
mu mer
i
als
er i Chem
com -com
t
e
a
l
E
e
M y&
T
&
og
et & edia
nol
M
ern
ech
Int
t
o
n
Na
In
rgy
Ene ion
t
a
ics
tom
Au oton re
Ph twa
f
l So
tr ia
s
u
d
Schlegelstraße 2 | 53113 Bonn
Phone: +49 (0)228-823001-00 | Fax: +49 (0)228-823000-50
E-Mail: [email protected]
ht tp: // www.high-tech-gruenderfonds.de
INVESTORS OF HIGH-TECH GRUENDERFONDS II
23
BioTOPics 47 | 6. Juni 2014 (3:02)
BioTOP-Report Business Location
Business Location
Excellent Services for Berlin-Brandenburg
The Berlin-Brandenburg region harbors outstanding potential for technological development and cooperation in its
high-density landscape of scientific and research institutions. The high concentration of international excellence
here facilitates interdisciplinary exchange, making it easier to realize new, landmark developments. At the same
time, the sheer number of players can make it difficult to find the right partner. The region’s Inward Investment and
Expansion team supports the healthcare and life sciences sectors with a full range of services, including marketing
activities at national and international trade shows. Our team has been in direct contact with the region’s companies
and scientific institutions for many years and can provide quick access to the right contacts and potential partners.
In 2013, Berlin Partner for Business and Technology supported
expansion projects and provided location services to 33 companies in Berlin, generating around 320 new jobs and a projected
investment of €63.9 million within the next three years. The list of
companies includes Cell Medica, CBR Biotech Strategies, Amal
Therapeutics and G&Life, an Italian company.
As in previous years, we organized a Berlin-Brandenburg Night
to mark the opening day of the BIO conference and exhibition
in Chicago. Once again, Bayer HealthCare was the lead sponsor.
Accepting the invitation from HealthCapital and Bayer HealthCare,
around 400 international guests from biotechnology and pharmaceutical companies attended the event.
In the same year, the Brandenburg Economic Development Board
(ZAB) supported approx. 130 investment and innovation projects
in the healthcare sector with a total investment volume of around
€27 m and the potential to create 220 new jobs. The successful
location of technology-based start-ups such as Glyco Universe,
ai-ibiomics and medneo deserves special mention. The team
at ZAB also supported the expansion investments of resident
companies co.don and Seramun. With the aim of positioning
the region’s companies in the global markets and presenting the
Berlin-Brandenburg Healthcare Industries cluster – HealthCapital – as one of Europe‘s leading healthcare sector locations, the
region exhibited at four important international fairs in 2013.
To provide support in the areas of internationalisation, technology
transfer and regulatory affairs to companies and scientific institutes
already located in Berlin and Brandenburg, we organized more
than 30 conferences, workshops and networking events last year.
The 2,000 accredited participants came from all over Germany.
Berlin-Brandenburg is also a life sciences hot spot for international delegations. At the 2013 BIONNALE, our annual biotechnology
conference, a group from Denmark presented its products and
services and networked with representatives from regional companies and scientific institutions.
In 2013, we kicked off the first “Health Week” for the capital region. Companies and organisations from the healthcare industries
took advantage of the opportunity to showcase their prevention,
diagnostics and therapy expertise and services. Over 90 companies and institutions organized more than 300 public events in
one week.
Dr. Rainer Knaus
Senior Vice President
Cell Medica Ltd.
Cell Medica, a leading T-cell therapeutics company and pioneer in the field, acknowledges the importance of the German market and especially the excellent conditions in Berlin.
The European commercial manufacturing facility within the
Campus Berlin-Buch biotechnology park was designed and
equipped to facilitate the high quality GMP-compliant production of patient-specific cell therapies for distribution across
Europe. Here in Berlin, we have found an outstanding scientific and industrial environment that allows us to attract highly
educated, well-trained personnel who are keen to help shape
this new era of cell-based therapeutics.
24
Carolin Clement
Head of Unit Biotech I Pharma
Berlin Partner for Business and Technology
Phone +49 30 46302-430
[email protected]
www.berlin-partner.de
Dr. Ute Hartmann
Head of Department Healthcare Industry/ Life Sciences
Brandenburg Economic Development Board (ZAB)
Phone +49 331 20029-250
[email protected]
www.zab-brandenburg.de
Life Sciences.
Living Research.
Berlin. Brandenburg.
A vibrant network.
Berlin-Brandenburg is one of Europe´s leading locations for the
Life Sciences. It is also an R&D capital that magnetically attracts
the world´s top scientists. Here you´ll find attractive funding
conditions, close linkages between business and science, the
highest concentration of R&D in Europe, a dynamic startup scene
and a multifaceted entrepreneurial environment made up of more
than 500 pharmaceutical, biotech and medical technology
companies. Come discover this one-of-a-kind landscape for
scientists and entrepreneurs.
www.healthcapital.de
BioTOP-Report Spotlight on European Business and Internationalization
Spotlight on European Business and Internationalization
The Enterprise Europe Network Berlin-Brandenburg
The Healthcare Industries cluster Berlin-Brandenburg has been an active member in a variety of European networks
and initiatives for many years. With the launch of Horizon 2020, the new EU research funding program, one network
in particular has taken center stage: the Enterprise Europe Network (EEN) Berlin-Brandenburg. With 20 experts on
Europe from the three participating host organizations Berlin Partner for Business and Technology, Brandenburg
Economic Development Board (ZAB) and the East Brandenburg Chamber of Commerce and Industry, it is the basis
for internationalization in the region – primarily for small and medium-sized companies.
Helping SMEs find business and technology partners throughout
Europe, the EEN provides information and advice on the innovation-oriented developments, initiatives and programs of the European Union. The EU Commission initiated the network, which
connects 100 regional consortia in approx. 60 countries in Europe
and the world to each other, at the beginning of 2008. Over 500
regional economic development institutions, chambers of industry and commerce and technology agencies with a total of 4,000
employees collaborate closely within the network. Supporting
small business is a cornerstone of the EU's drive for growth and
jobs: 99% of all companies in the EU are small and medium-sized
(SMEs) and they account for 67% of the jobs. The EEN’s services
are tailored to SMEs, but are also available to all other businesses,
universities and research centers.
Services tailored to small companies
Taking part in an EU-funded research project is a great way to
boost a company's competitiveness. SMEs need the right partners
for successful projects, and the Enterprise Europe Network helps
by identifying companies' needs and potential and connecting
them with each other. The network does not fund any projects itself,
but helps companies to tap into the EU's funding opportunities.
Elias Zafirakos
Science & Innovation Network Manager
Biopeople Københavns Universitet
The matchmaking session organized by the Enterprise Europe
Network gave the Danish delegation a valuable opportunity
to meet with potential German collaboration partners at the
Bionnale 2013. The EEN setup made it possible to plan and
book meeting ahead of the conference and was a great help in
exposing the Danish Delegation towards the German audience.
26
Horizon 2020 leads the way – it is the EU's latest research funding
program, launched in December 2013 with a volume of almost
€80 billion. Normally, its consortia must consist of companies from
three different EU countries, but the EEN also assists SMEs with
this aspect. The network’s business cooperation database is one
of the world's largest and contains thousands of company profiles. Companies can meet potential business partners in person
at EEN’s matchmaking events, which often take place at international fairs to help keep travel and accommodation costs low.
For example, the Enterprise Europe Network Berlin-Brandenburg
played a major role in opening up the annual BIONNALE – the key
biotechnology and pharmaceutical industry meeting place in the
capital region – to an international audience. Almost 80 participants, including a larger company delegation from partner country Denmark, gathered for the matchmaking event EEN organized
in 2013. On the day of BIONNALE 2013, the participants held
around 160 meetings.
The regional EEN contact point for all themes relating to the
healthcare industries:
Wolfgang Korek
Project manager EEN Healthcare Industries
Phone +49 30 46302-518
[email protected]
www.berlin-partner.de
Dajana Pefestorff
Project manager International Business
Director EEN
Phone +49 331 660-3234
[email protected]
www.zab-brandenburg.de
BioTOP-Report 2014
Alacris Theranostics GmbH
Alacris Theranostics GmbH is a Berlin-based
Alacris provides extensive bioinformatics
for effective development and approval of
company with the mission to exploit next gen-
expertise and well equipped facilities includ-
drugs for the pharmaceutical industry in 'Vir-
eration sequencing and other omics data
ing a next generation sequencing lab for
tual Clinical Trials'.
through its predictive modelling system Mod-
clinical application and a powerful IT infra-
CellTM for drug development and person-
structure. Alacris works together with clinics
alised medicine in oncology. This approach
and industry leaders in the fields of person-
Address
was originally developed at the Max Planck
alised medicine, biomarker application, and
Institute for Molecular Genetics in Berlin and
drug development.
Fabeckstraße 60-62
is exclusively licensed to Alacris.
Phone +49 30 84312250
With
its
proprietary
ModCell™
System,
14195 Berlin · Germany
Alacris Theranostics applies a new, revolu-
[email protected]
tionary systems biology modelling approach
www.alacris.de
to better match patients to therapies and
therapies to patients. ModCell™ provides a
'Virtual Patient' model allowing predictive
analysis of cancer patient samples on therapy outcome. ModCell™ integrates next generation sequencing derived genome and
Unlocking The Power Of
Individualised Medicine
transcriptome information with a generic cancer model of molecular processes in tumour
onset and progression. ModCell™ facilitates
the simulation of the effects of different
drugs for the development of new personalized medicine approaches in the clinic and
co.don AG
The biopharmaceutical company based near
and reha
bilitation times are significantly
Berlin is one of the leading specialists world-
reduced for both doctor and patient. Because
wide in cell cultivation for the regenerative
no external materials are used, the risks of
treatment of articular cartilage defects and
rejection, inflamma
tion and infection are
spinal disc defects. In many cases the use of
reduced to the minimum. co.don® AG is certi-
the company's patented pharmaceutical
fied in accordance with DIN EN ISO
product can avert the need for joint and spi-
9001:2008. Furthermore, production, quality
Address
nal disc replacement surgery. Orthopaedic,
control and quality assurance have been cer-
co.don AG
accident and neuro-surgeons are increas-
tified in accordance with European Guide-
Warthestraße21
ingly applying these regenerative treatment
lines for Good Manufacturing Practice (EU-
14513 Teltow · Germany
methods. co.don® AG manufactures cell-
GMP). co.don® AG‘s technological, produc-
based tissue engineering therapeutics to the
tion and regulatory expertise makes the com-
Contact
highest quality standards. Its products repre-
pany a first mover in the market for biological
Matthias Meißner, M.A.
sent a revolutionary process in the biological
cartilage and disc tissue replacement and a
Head Corporate Communications/IR/PR
replacement of damaged articular cartilage
provider of highly effective, safe treatment
Phone+49 3328 4346 0
and invertebral disc by building up strictly
options not only resulting in relief of pain, but
Fax
autologous tissue without the involvement of
actual repair of damaged tissue.
[email protected] · www.codon.de
+49 3328 4346 43
any external carrier materials or additives.
The application of the products may be mini-
co.don® AG is listed on the Frankfurt Stock
mally invasive or arthroscopic and so surgery
Exchange (ISIN: DE000A1K0227).
27
BioTOP-Report 2014
Evestra GmbH
Evestra GmbH, founded in July 2008, is a
includes product ideas with known com-
Address
fully owned subsidiary of Evestra Inc. located
pounds as well as New Chemical Entities.
Evestra GmbH
as the development and commercialization
Evestra is conducting research and product
center for Europe and ROW. Evestra’s mis-
development in a number of in-demand, but
in San Antonio Texas. Evestra GmbH serves
Britzer Straße 26
sion is to develop and commercialize steroid-
as yet unmet, medical need areas of wom-
EU Contact
based female healthcare products. The
en’s health such as hormonal-dependent
Prof. Klaus Nickisch · Managing Director
development
breast cancer and endometriosis. The com-
Phone +49 30 66509642
pany is also pursuing different projects in
[email protected]
fertility control, e.g. a new estrogen for oral
www.evestra.com
strategy
of
the
company
contraception, with superior pharmacological properties compared to the standard
drug ethinyl estradiol.
Several patents on new composition of matter, new technical processes and use patents
have been filed during the last years and
support the strong intellectually property
position. Evestra is concentrating on R&D
and will seek more partners for commercialization.
More detailed information can be found on
our website.
LGC Genomics
At LGC we offer a full range of high quality
iaturisation for more flexible, cost-effective
We operate sales offices in the UK, Germany
PCR reagents, custom genotyping assays,
workflow solutions in high-throughput geno-
and the USA, with sales representatives
genomic services and workflow solutions for
typing. In addition, customers are offered
throughout Europe, the USA and Australia as
DNA sample preparation and downstream
industry leading proprietary nucleic acid
well as distributors in China, Korea and other
processing (www.lgcgroup.com/genomics).
extraction, sequencing and genotyping ser-
key emerging territories.
vices from our labs globally.
Address
Our proprietary KASP™ allelic discrimination
chemistry and has optimised workflows for
„We use what we sell and sell what we use”
1536 microtitre plates that enable assay min-
is key to the products and services we pro-
Ostendstrasse 25 · TGS Haus 8
vide.
Our portfolio includes:
[email protected]
kk Genotyping services, assays and
www.lgcgroup.com/genomics
LGC Genomics GmbH
Phone +49 30 53042200
reagents
kk Sanger and next-generation sequencing
services
kk DNA and RNA extraction products and
services
kk PCR reagents and consumables
kk Laboratory instrumentation
kk Plate sealers
kk Liquid handling robots
kk High-throughput PCR thermal cyclers
kk Plate readers
28
BioTOP-Report 2014
Metanomics Health GmbH
kk Wide metabolite coverage via combination of unbiased and targeted platforms
kk Unique tox mode of action prediction
through MetaMap ®Tox database
kk Excellence in systems correlation analy-
development (e.g. PK/PD, patient stratification, efficacy and safety markers)
kk Companion diagnostic development
kk Cell culture & bioprocess optimization
kk Biospecimen quality control
sis of complex gene function relationships
kk Highly robust and reproducible results
Address
Tegeler Weg 33 · 10589 Berlin · Germany
Major R&D-Topics
Metanomics Health – a BASF Group compa-
In cooperation with academic institutes and
Contact
ny – combines comprehensive Metabolite
clinical experts Metanomics Health is run-
Dr. Tim Bölke · Managing Director
Profiling (metabolomics) with biomedical
ning a large-scale diagnostic biomarker pro-
Phone+49 30 34807 400
data interpretation. Metabolite Profiling is
gram. Areas include metabolic syndrome,
Fax
defined as the parallel analysis of multiple
heart failure, prostate cancer and pancreatic
[email protected]
endogenous and xenobiotic metabolites in
cancer to mention a few.
www.metanomics-health.de
+49 30 34807 401
biological systems. The core expertise of
Metanomics Health resides in discovery and
Market Segments
validation of biomarkers.
Metanomics Health provides its services to
Technologies
companies. Technology applications include:
kk Metabolite profiling platform with more
kk Mechanism of action studies
pharmaceutical, diagnostics and nutrition
than 75 GC-MS and LC-MS/MS instru-
kk Mechanism of toxicity studies
ments
kkTranslational and clinical biomarker
nanoPET Pharma GmbH
nanoPET is a biopharmaceutical company
The first nanoparticular tracers for clinical
long-standing industry expertise our team
specialized on R&D, manufacturing and mar-
PET: nanoPET prepares the clinical develop-
has
keting of innovative drug substances for
ment of its patented technology platform:
research & development.
Diagnostic Imaging. We focus on relevant
inorganic nanoparticular tracers for cell- and
cardiovascular, oncological and neurological
molecular-specific positron emission tomog-
indications as well as on regenerative medi-
raphy (PET).
cine. Nanotechnology is a key element of our
business. We operate in three major areas.
attained
in
the
pharmaceutical
Address
nanoPET Pharma GmbH
Robert-Koch-Platz 4
Viscover™ imaging agents – a landmark in
small animal imaging: As animal imaging is
rapidly gaining relevance in pharmaceutical
Contact
research, we are delighted to offer you an
Dr. Andreas Briel · CEO
exciting portfolio of specialized pre-clinical
Phone +49 30 890 49740
imaging agents covering the principal imag-
[email protected]
ing modalities (MRI, CT, Ultrasound, Optical
www.nanopet-pharma.com
Imaging, SPECT & PET). Get a detailed
insight into our product portfolio and download a free copy of our imaging guide on
www.viscover.com
Consulting and Service tailored to your
needs: As a technology and service provider,
we offer our expertise to biopharmaceutical
companies and imaging equipment manufacturers. Our customers benefit from the
29
BioTOP-Report 2014
Getting your innovation going.
Our tailored financing are your key to success. Our consultants look forward to meeting you.
Contact us:
Phone: +49 (0)30 / 2125-4747
E-mail: [email protected]
www.ibb.de/wachsen
140305_IBBanz_biotop12_210x148.indd 1
05.03.14 12:22
ORGANOBALANCE GmbH
Exploring and managing microbial
biodiversity
gens, produce new bioactives, neutralize
ORGANOBALANCE works in collaboration
malodorous or toxic substances and synthe-
with partners and grants licenses for own
size high titers of valuable compounds.
product developments.
Address
ORGANOBALANCE explores the potential of
probiotic bacteria and yeasts for new prod-
ORGANOBALANCE
uct developments in food, feed, personal
resources, which are gathered in the compa-
draws
on
natural
care, and for the pharmaceutical industry or
ny-owned collection of 8000+ microbial
Gustav-Meyer-Allee 25
the production of fine chemicals. From a
strains, mostly originating from foodstuffs.
large collection of microorganisms, specific
ORGANOBALANCE uses its OASSYS® bioas-
strains are selected to e.g. inactivate patho-
says for highly efficient screenings. The plat-
Contact
form allows to quickly identify the most suit-
Dr. Christine Lang · CEO
ORGANOBALANCE GmbH
able strains from the microbial collection for
Phone +49 30 46307200
targeted applications.
Fax
+49 30 46307210
[email protected]
ORGANOBALANCE has a broad expertise in
the field of yeast metabolic engineering. This
includes designing and developing new production strains for industrial biotechnology
applications. Specific strains of Saccharomyces cerevisiae, which carry engineered biosynthesis pathways for the environmentally
friendly production of carboxylic acids, terpenoids, steroids and other lipid compounds
are available.
30
www.organobalance.com
BioTOP-Report 2014
syneed medidata GmbH
Are you getting the whole picture? We Do.
tional non-interventional studies and gets
provide the expertise you need for turning
and end-users. syneed medidata GmbH
data into results.
syneed medidata GmbH is an independent,
combines experience with the quality, dedi-
privately owned contract research organiza-
cation and ﬂexibility of a midsized organiza-
tion (CRO) providing end-to-end services for
tion. ness in 1985, we have constantly expanded
our service portfolio. In 1995 we conducted
our first medical device study, and in the
same year we started our Imaging Core Lab
operations (see below). Moreover, we offer
the complete scope of Pharmacovigilance
services for development projects as well as
for marketed products (drugs and medical
devices). Our notion of service is based on
the knowledge that every project is unique –
and that custom-tailored solutions serve best.
This is reflected in all our actions. As an
example, for data capture our clients may
Address
syneed medidata GmbH
phase I to phase IV clinical trials and for noninterventional studies. Commencing busi-
So, for almost any trial you can think of, we
enthusiastic feedback from both customers
Cicerostraße 21
Full clinical and biometric services
for clinical trials and non-interventional
studies
Operational services offered in EU, CEE,
Russia and USA through our established
alliance of partner CROs
Very high staff retention - stable,
experienced teams delivering projects
on time and with highest quality
Phone +49 30 31172751 00
www.medidata.de
[email protected]
Contact
Dr. Christian Hucke
Clinical Program Director
[email protected]
Pharmacovigilance and Imaging services
for development projects and marketed
products
Best value for money due to
tailor-made services
choose between paper and different EDC
solutions, including our proprietary EDC system, which has been developed for multina-
syneed imaging
syneed imaging, the Medical Imaging Core
Within almost 20 years of operation we have
All study data are hosted solely in Germany
Lab of syneed medidata GmbH, offers solu-
managed trials in various indications (oncol-
on our servers maintained by own IT staff.
tions for study planning, protocol develop-
ogy, neurology, radiology, PET diagnostics,
Address
ment, site evaluation, image collection and
devices) and modalities, and established an
processing and conduct of central indepen-
extensive network of medical experts who
syneed imaging & syneed medidata GmbH
dent reviews with a wide variety of criteria
support us as consultants and independent
Cicerostraße 21
(e.g. RECIST, 1.0 and 1.1, Choi, Cheson, irRC,
readers. Our experience, flexibility and pric-
RANO, PERCIST, mRECIST).
ing especially for early phase trials are highly
Phone +49 30 31172751 00
valued by Biotech clients.
Contact
John Uiters
Director Medical Imaging Services
[email protected]
31
BioTOP-Report
P Bioparks
etworks
PNScientific
P CompaniesInstitutions
P
Biotech Networks
kkBioTOP Berlin-Brandenburg
kkBioHyTec Network for Biohybrid Technologies
kkBioResponse
kkCenter for Molecular Diagnostics and Bioanalytics (ZMDB)
kkDiagnostikNet-BB
kkNetwork Glycobiotechology Berlin-Brandenburg
kkRegenerative Medicines Initiative Berlin-Brandenburg
kkRiNA Network for RNA Technologies
Scientific Institutions
kkBerlin-Brandenburg Center for Regenerative Therapies (BCRT)
kkBrandenburg University of Technology (BTU)
kkCharité – Universitätsmedizin Berlin
kkFraunhofer Institute for Applied Polymer Research (IAP)
kkFraunhofer Institute for Biomedical Engineering (IBMT)
kkFreie Universität Berlin (FU)
kkGerman Heart Instiute Berlin (DHZB)
kkGerman Institute of Human Nutrition (DIfE)
kkGerman Rheumatism Research Center (DRFZ)
kkHumboldt-Universität zu Berlin (HU)
kkInstitute of Biomaterial Sciences, Helmholtz-Zentrum Geesthacht
(Teltow)
kkLausitz University of Applied Sciences
kkLeibniz-Institute for Agricultural Engineering Potsdam-Bornim
(ATB)
kkLeibniz-Institut für Molekulare Pharmakologie (FMP)
kkLeibniz-Zentrum für Agrarlandschaftsforschung (ZALF) e. V.
kkMax Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
kkMax-Planck-Institute for Colloids and Interfaces
kkMax Planck Institute for Infection Biology
kkMax Planck Institute for Molecular Genetics
kkMax Planck Institute of Molecular Plant Physiology
kkRobert Koch Institute
kkTechnische Universität Berlin (TU)
kkUniversity of Applied Sciences Berlin (HTW)
kkUniversity of Applied Sciences Wildau
kkUniversity of Potsdam
32
BioTOP-Report
IFHI
33
BioTOP-Report Biotech Parks
Biotech Parks
The BioCampus Network Berlin-Brandenburg
Berlin-Brandenburg boasts seven biotechnology parks, which offer optimal space for the specific requirements
of every company. This geographic concentration of specific biotech parks is unique in Germany and probably
in all of Europe. The parks differ in their offers and strategic focus and provide ideal conditions for newcomers.
More than half of the 232 companies are currently utilizing the infrastructure of a publicly or privately managed
park. In addition, the young companies benefit from the closeness to science and the permanent contact and
exchange.
berlinbiotechpark
In the very heart of Berlin
The infrastructure includes conference facilities as well as
works security and waste disposal services. It is rounded off
by production-related services such as plant engineers and
laboratory technicians, industrial safety engineers, a medical
service as well as best-buy services and communication services. Offering flexible growth potential, production-orientat-
berlinbiotechpark Management GmbH · Herr Frank Elsner
ed media equipment and comprehensive industrial-specific
Max-Dohrn-Straße 8–10 · 10589 Berlin
services and infrastructure, berlinbiotechpark is particularly
Phone +49 30 20364205 · Fax +49 30 20364190
attractive for growing internationally orientated technology
[email protected] · www.berlinbiotechpark.de
companies. Furthermore, it offers a permanent base in Berlin
berlinbiotechpark is located on a 86,000 sq.m. site in the
by their limited start-up funding. The inner-city location and
for developing companies that have outgrown the size allowed
very heart of Berlin, currently offering a total of approx.
the excellent public transport guarantee short ways to all sci-
63,000 sq.m. of office, laboratory and production space, with
entific institutions and hospitals of the city.
a building potential for another 45,000 sq.m. of rental area.
The site, which is home to Biotech/Pharma/Service Companies is supplied with a complete range of media for laboratory
Biotech Campus Potsdam
Research on the Waterfront
and production purposes, with production steam with possibility to upgrade to HP steam, power supply, compressed-air,
nitrogen and other inert gases, cooling water and DI-water , all
being provided at favorables rates.
Steinstraße 104-106 · 14480 Potsdam
Phone +49 331 6601628 · Fax +49 331 6601699
[email protected] · www.biotechcampus.de
Contact: Gabriele Ziegler
Just a few minutes away from Potsdam’s central railway station in the direction of Caputh, Biotech Campus Potsdam
is located on the Hermannswerder peninsula in the river
Havel. It is owned and operated by Biotech Campus Potsdam GmbH, a fully owned subsidiary of the Investment Bank
of the State of Brandenburg.
34
The biotechnology center is housed in four buildings dating
from around 1,900 and one modern complex and offers a
Biotechnology Park Luckenwalde
Space for Expansion
total of 11,400 sq.m. of laboratory, office, greenhouse and
storage space. With such a large facility at its disposal, it offers biotechnology companies an ideal environment for successful operations. All labs are approved as S1 laboratories
and meet the building requirements for approval as S2 labs.
The Hermannswerder site also includes an S3 laboratory as a
special resource. The beautiful, park-like setting of the pen-
Biotechnologiepark Luckenwalde · c/o SWFG mbH
insula offers an excellent environment for research activities.
Im Biotechnologiepark, TGZ I · 14943 Luckenwalde
The island hotel and a conference center are located directly
Phone +49 3371 681100 · Fax +49 3371 681105
next to the campus.
[email protected] · www.bio-luck.de
Contact: Dipl.-Ing. Christoph Weber · Director
The site also includes a self-service restaurant and small island shop. The philosophy of Biotech Campus Potsdam was,
Located just 25 miles from the new Berlin-Brandenburg In-
and still is, to create the freedom for research and innovation
ternational Airport (BBI) in the district of Teltow-Flaeming,
in the high-tech sector of biotechnology. Reputable firms from
the Biotechnology Park Luckenwalde is one of the most
the industry can indeed be found here.
modern facilities of its kind in Germany. It is home to 35
companies from Germany, USA, UK, Korea and Israel with
about 500 employees.
The work carried out by resident companies is multi-faceted,
ranging from green biotechnology, the development of vac-
Companies in the park focus on the development and produc-
cines, the development of pharmacologically active substanc-
tion of pharmaceuticals, recombinant proteins and diagnostic
es based on plant materials, the development and production
kits, biological/chemical substances for biotech and pharma-
of PCR tests for food testing and preclinical contract research
ceutical applications, as well as fine chemicals. There are also
right through to medical technology. A total of 200 employees
suppliers of medical technology, analytical services, and a
work on the site.
Biotech Education Center. Technical Equipment comprises
completely furnished S2 laboratories (safety workbench, autoclave, dishwasher, deionized water, water purification system,
central media supply (compressed air, N2, CO2, O2, H2), storage and cool rooms, pharmaceutical clean rooms category
35
(B/C), 400 MHz NMR spectrometer, meeting rooms, confer-
start-up funding, we additionally hold 80,000 sq.m. developed
ence hall (300 seats), library, restaurant with catering service.
industrial property ready for expansion.
The entire central technique meets GMP/ISO 9001 specifications. The park management offers comprehensive, individual
services and advice during the settlement and development
of firms, including support for the recruitment of the key staff.
Currently the park offers 9,000 sq.m. labs and office space,
and additional 100,000 sq.m. industrial property ready for
expansion. The park is part of an international and regional
network to assure access regional and to funding sources and
cooperation with universities and hospitals.
Co:bios Technologiezentrum
Service for all stages of growth and expansion
With our holistic approach combining settlement, development,
construction and licensing issues to the point of traditional
management consulting, and on the background of the high
density of innovative, research-intensive and service-oriented
companies on the co:bios biotechnology park Hennigsdorf
co:bios Technologiezentrum GmbH
we can initiate interesting synergy effects for your business
Neuendorfstraße 20 a · 16761 Hennigsdorf
model. Within this locational advantages the co:bios biotech-
Phone +49 3302 2021250 · Fax +49 3302 2021257
nology park became a magnet for the international healthcare
[email protected]
industry and the percentage of international settlements on
www.cobios-technologiezentrum.de
this site is growing, for example from USA, South America,
VAI and Asia.
Located in the northwest of Berlin, the co:bios Technology
Center in Hennigsdorf is the congested urban area in Berlin-Brandenburg of biotechnology and life science. In the last
15 years more than 30 companies with approximately 700
Campus Berlin-Buch
Interaction of Research, Clinics and Companies
international employees have settled on this site.
On more than 10,000 sq.m. we offer service space for
extension to clean rooms (class D/E/F), S1 labs, DI-water supply, compressed air supply, special gas supply, state of the
art data communication, meeting rooms, conference hall and
more. The building and central technique requirements also
Robert-Rössle-Straße 10 · 13125 Berlin
meet the fulfillments for S2 labs for GMP/ISO 9001 based pro-
Phone +49 30 94892511 · Fax +49 30 94893812
duction specifications. As a center of excellence for biotech-
[email protected] · www.bbb-berlin.de
nology and life science we have a selected portfolio of service
Contact: Dr. Andreas Mätzold · Executive Manager
and advice to young start-ups as well as medium sized com-
Dr. Ulrich Scheller · Executive Manager
panies, in aim to support them across all stages of company
growth. For those companies who have outgrown their limited
36
Berlin-Buch is the location of one of the largest biotechnology parks in Germany, with 31,000 square meters of scalable
lab and office space for start-ups and maturing companies.
Berlin Adlershof
Germany’s leading Science- and Technology
Park
Situated to the northeast of the city, the Berlin-Buch Campus
is currently home to 56 companies, 41 of which are biotech
companies; the rest provides support services.
Beside the BiotechPark the Max Delbrück Center for Molecu-
Adlershof Zentren für Biotechnologie und Umwelt
lar Medicine, the Leibniz Institute for Molecular Pharmacology
WISTA-MANAGEMENT GMBH
as well as clinical groups from the Charité University Hospi-
Rudower Chaussee 17 · 12489 Berlin
tal within the Experimental and Clinical Research Center are
Phone +49 30 63922221 · Fax +49 30 63922212
part of the Campus community. The Campus gives access to
[email protected] · www.adlershof.de
high-end technology platforms, state of the art infrastructure,
Contact: Heidrun Terytze
interdisciplinary communication, projects and expertise in a
Head of Center for Biotechnology and Environment
wide range of items, especially in translational research. The
BiotechPark at the Campus Berlin-Buch offers:
kk Immediately available lab and office space
kk Excellent research and clinical expertise on-site
kk Training programs for personnel on spot
kk An international community of like-minded people
kk Interdisciplinary networks and platforms
Berlin Adlershof focuses on photonics and optical technologies, material and microsystems technology, information
and media technology, as well as biological, and environmental technology. There are currently 25 biotech companies in Adlershof occupying 18,200 sq.m. of lab and office
space. The companies focus on:
kkBiotechnology products and procedures development
kkPharmaceutics, medicine, and medicine technology
The BiotechPark including the Innovation and Incubation Cen-
kkAnalytics
kkEnvironmental technology
ter is managed by BBB Management GmbH Campus Berlin-Buch. Acting as a full-service company BBB’s main tasks
Technical Equipment comprises laboratories with a basic
are the settlement, accompanying and support of Biotech
equipment: security-lockers, laboratory basins, work bench-
businesses.
es, vacuum supply, preliminary setup for supply of pure gases and compressed air, reconfiguration for further media and
gases, central cooling, preliminary setup for cold water supply
37
in rental areas, refitting of heat exchanger by the tenant pos-
The GO:IN Innovation Center offers young technology-based
sible. Adlershof. Science at Work.
companies and entrepreneurs a range of office and laboratory spaces along with extensive services and optimal support
for a successful market launch. Close proximity to the other
Science Park Potsdam-Golm
Connecting Excellence
players at Potsdam-Golm and the intensive networking of the
different institutions and companies here offer perfect conditions for the development and exploitation of synergies.
Standortmanagement Golm GmbH
Am Mühlenberg 11 · 14476 Potsdam-Golm
Phone +49 331 237351130
www.wissenschaftspark-potsdam.de · www.goin-potsdam.de
Contact: Friedrich W. Winskowski · Managing Director
Science
Park
Potsdam-Golm
combines
cutting-edge
international research and the training of young scientists
in a high-powered location in the immediate vicinity of the
German capital Berlin. Alongside the Faculty of Science and
the Human Sciences Faculty of the University of Potsdam,
three Institutes of the Max Planck and two of the Fraunhofer
Society as well as an innovation center with currently
22 companies operate in Brandenburg’s largest science park.
More than 2,500 people work at Potsdam-Golm and more
than 9,000 students are pursuing their academic qualifications here. The pleasant and very family-friendly working environment on the edge of a nature conservation area, the high
quality of life in and around Potsdam and continuous growth
make Potsdam-Golm a highly attractive location. Professional site management is extending the park infrastructure and
fosters the integration of the capabilities and interests of
all institutions, associations and companies that operate at
Science Park Potsdam-Golm.
38
BioTOP-Report Addresses
Addresses
Addresses
Networks40
Biotech Parks
40
Other Parks
41
IP Asset Management 41
Universities and Research Centers
41
Banks and VCs
41
Supporting Organisations
42
Pharmaceutical Companies
42
Contract Manufacturers
44
Contract Research Organisations
44
Biotech Companies
46
For Companies on the Rise
Equity Financing – building
on your strengths!
Are you looking to expand your business and maximize on growth prospects
in the technology sector in Germany? Yet, you require some support and
equity financing to get your project successfully underway in a new marketplace? Then, we are the right partner for you!
We pride ourselves in providing the best in equity financing to our 150 corporate clients totalling over 150 million in strategic financing. We are dedicated
to assisting our customers to advance their businesses in new areas and to
enable sustainable growth of business and even greater success.
Foto: ILB
Remember, your success is our success. Let us be part of your success story!
Contact us now.
www.ilb.de
Networks
BioHyTec – Verein für Bioanalytik BioHyTec is the biohybrid technology network in the life sciences cluster of Berlin-Bran- biohytec.de
und Biohybrid-Technologien e. V. denburg. This new field of technology is the interface between biosensor development
and microsystems technology. Biohybrid systems open up new applications in pharmaceutical research, clinical diagnostics, food analysis and genetic engineering.
BioResponseNetzwerk
BioResponse is an interdisciplinary research and development organisation with mem- bioresponse.de
bers from Brandenburg, Berlin and Saxony. It focuses on the development and marketing of multiplex assays for diagnostic antibody identification based on the proprietary
BioResponse technology, which is comprised of fully automated image analysis of fluorescence-encoded microparticles and labelled cell structures.
DiagnostikNet-BB Netzwerk
Diagnostik Berlin-Brandenburg
DiagnostikNet-BB is the Berlin-Brandenburg network for in vitro-diagnostics. Members diagnostiknet-bb.de
include biotech companies as well research institutes and clinics. Main objectives of
the network are: Development of system solutions, optimizing compatibility, close cooperation with leading clinicians and joint marketing.
Health Capital BerlinBrandenburg
In order to develop the scientific and economic position of the region, the governments healthcapital.de
of the states of Berlin and Brandenburg have put the master plan “Healthregion Berlin
Brandenburg” into effect. Its key to a continued success is a continued close interplay
between research, development and education7vocational training with production,
application and supply. All of these activities are integrated and coordinated through
the Network “Gesundheitswirtschaft Berlin Brandenburg” under the brand of “HealthCapital”.
Regenerative Medicine Initiative
Berlin-Brandenburg
The mission of the RMIB is to promote the Berlin-Brandenburg region as a center of rmib.de
excellence for Regenerative Medicine particularly for cell-based medical biotechnology. The RMIB promotes networking in the field and supports the further development of
clinical studies and education programs. The initiative fosters the collaboration between
universities, research institutes, companies (including SMEs) and organizations in the
field of science and technology.
RiNA -Netzwerk RNATechnologien
The RNA-Network provides ongoing support and funding for the development of RNA rna-network.com
technologies with the goal to commercialize the results. One main focus is the improvement and application of the RNA interference technology. Further projects develop RNA
aptamers, cell-free protein biosynthesis systems and analyse the structure and function
of RNA molecules. The RiNA RNA-Network encourages co-operation and information
exchange between academy and industry.
Zentrum für Molekulare
Diagnostik und Bioanalytik
The Centre for Molecular Diagnostics and Bioanalytics (ZMDB) is a virtual centre op- zmdb.de
erated under the auspices of the Fraunhofer Institute for Biomedical Technology and
the Charité – Universitätsmedizin Berlin in close cooperation with the region’s company
networks. The aim is to bring together regional expertise in basic research, technology
development, clinical research and industrial cooperation initiatives to set up joint projects that will speed up the development of in vitro-diagnostics “Made in Berlin-Brandenburg”.
Biotech Parks
berlinbiotechpark
berlinbiotechpark is located on a 86,000 m² site in the very heart of Berlin, currently berlinbiotechpark.de
offering a total of approx. 57,000 m² of office, laboratory and production space, with
a building potential for another 45,000 m² of rental area. Offering flexible growth potential, production-orientated media equipment and comprehensive industrial-specific
services and infrastructure, berlinbiotechpark is particularly attractive for growing internationally orientated technology companies.
Just a few minutes away from Potsdam’s central railway station in the direction of Ca- biotechcampus.de
puth, BIOTECH CAMPUS POTSDAM is located on the Hermannswerder peninsula in
the river Havel. It is owned and operated by BIOTECH CAMPUS POTSDAM GmbH, a
fully owned subsidiary of the Investment Bank of the State of Brandenburg.
Biotechnologiepark Luckenwalde Located just 30 miles south of Berlin and 25 miles from Berlin-Brandenburg Internation- bio-luck.de
al Airport in the rural district of Teltow-Flaeming, the Biotechnology Park Luckenwalde
is one of the most modern facilities of its kind in Germany. It is home to 35 companies
with about 500 employees from Germany, USA, UK, Korea, and Israel.
Co:bios Technologiezentrum
GmbH
The co:bios Technology Center in Hennigsdorf offers affordable rental opportunities cobiosand a selected portfolio of services and advice to young start-ups as well as medi- technologiezentrum.de
um-sized companies. Therefore Hennigsdorf is a center of excellence for life sciences,
especially in the field of red biotechnology and medical technology.
Campus Berlin-Buch bbb
Management GmbH
Berlin-Buch is home to one of the largest biotechnology parks in Germany, with 26.000 bbb-berlin.de
square meters of scalable lab and office space for start-ups and maturing companies.
Situated to the northeast of the city, the campus is currently home to 56 companies, 41
of which are biotech companies; the rest provide support services.
Adlershof Zentren für
Biotechnologie und Umwelt
Berlin Adlershof is one of the most successful high-tech locations in Germany with adlershof.de
focus on Photonics and Optics, materials and microsystems and media, biotechnology,
and environment. There are currently 25 biotech companies in Adlershof occupying
18,200 sq.m of lab and office space.
40
Other Parks
GO:IN Golm
Innovationszentrum GmbH
Science Park Potsdam-Golm is one of the most innovative and promising locations in wissenschaftsparkBrandenburg. In the GO:IN facility, innovative companies will find an excellent working potsdam.de
environment where they will benefit from the synergy effects of the location and the goin-potsdam.de
specific equipment offered by its laboratories. The location provides a wide range of
services and consulting, as well as integration into the existing regional networks.
Innovationspark Wuhlheide
So far 140 companies have decided to locate at the Wuhlheide Innovation Park, where ipw-berlin.de
the creative environment and service-oriented management provide important stimuli
with respect to product development and innovation. Our companies have attractive
office accommodation, workshops, laboratories and service areas at their disposal.
Furthermore, they also have the opportunity to acquire fully developed investment sites
for the evolution of their company! The location stands for successful new businesses,
growth and long-term perspectives.
IP Asset Management
Ascenion
Ascenion advises public life science research institutions, universities, hospitals, free- ascenion.de
lance inventors and companies in all aspects of intellectual property asset management.
ZukunftsAgentur Brandenburg
GmbH Brainshell
Brainshell is an independent consulting agency specializing in intellectual property brainshell.de
services for businesses.Brainshell manages and markets the patent portfolios of all
colleges, universities, and research institutes in the State of Brandenburg.
Universities and Research Centers
BAM Federal Institute for Materials Research and Testing
bam.de
Berlin-Brandenburg Center for Regenerative Therapies (BCRT)
b-crt.de
BfR Federale Institute for Risk Assessment
bfr.bund.de
Brandenburg University of Technology
tu-cottbus.de
Charité - Universitätsmedizin Berlin
charite.de
Deutsches Rheuma-Forschungszentrum Berlin
drfz.de
Fraunhofer Institute for Applied Polymer Research (IAP)
iap.fraunhofer.de
Fraunhofer Institute for Biomedical Engineering (IBMT)
ibmt.fraunhofer.de
Freie Universität Berlin
fu-berlin.de
German Heart Instiute Berlin
dhzb.de
German Institute of Human Nutrition (DIfE)
dife.de
Humboldt-Universität zu Berlin
hu-berlin.de
htw Berlin – University of Applied Sciences
htw-berlin.de
Institute of Biomaterial Sciences, Helmholtz-Zentrum Geesthacht (Teltow)
hzg.de
Institute for the Reproduction of Farm Animals Schönow Inc.
ifn-schoenow.de
Lausitz University of Applied Sciences
fh-lausitz.de
Leibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB)
atb-potsdam.de
Leibniz-Institut für innovative Mikroelektronik
ihp-microelectronics.com
Leibniz-Institut für Molekulare Pharmakologie (FMP)
fmp-berlin.de
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
mdc-berlin.de
Max Planck Institute for Infection Biology
mpiib-berlin.mpg.de
Max Planck Institute for Colloids and Interfaces
mpikg.mpg.de
Max Planck Institute for Molecular Genetics
molgen.mpg.de
Max Planck Institute of Molecular Plant Physiology
mpimp-golm.mpg.de
Robert Koch Institute (RKI)
rki.de
Technische Universität Berlin (TU)
tu-berlin.de
University of Applied Sciences Berlin
beuth-hochschule.de
University of Applied Sciences Wildau
tfh-wildau.de
University of Potsdam
uni-potsdam.de
Banks and VCs
BC Brandenburg Capital GmbH
bc-capital.de
Berliner Sparkasse-Kompetenzzentrum Gründungen und Unternehmensnachfolge
lbb.de
Berliner Volksbank eG
berliner-volksbank.de
41
Banks and VCs
bmp Life Science AG
bmp.com
Business Angels Club Berlin
bacb.de
Commerzbank AG
commerzbank.com
Creathor Venture
creathor.de
Demeter Partners
demeter-partners.com
Deutsche Bank AG
db.com
High-Tech Gründerfonds Management GmbH
high-tech-gruenderfonds.de
IBB Beteiligungsgesellschaft mbH
ibb-bet.de
Investitionsbank Berlin
ibb.de
Investitionsbank des Landes Brandenburg
ilb.de
KfW-Mittelstandsbank
kfw-mittelstandsbank.de
Peppermint Venture Partners GmbH
peppermint-vp.de
Ventegis Capital AG
ventegis-capital.de
XLHealth
xlhealth.de
Supporting Organisations
Berlin Partner für Wirtschaft und
Technologie GmbH
Support of international and domestic companies in all issues regarding locating berlin-partner.de
to Berlin.
Coaching Bonus
Specific Coaching offers for innovative high tech companies.
coachingbonus.de
Investitionsbank Berlin (IBB)
Company financing and consultation on subsidies and processing grant
applications in Berlin.
ibb.de
Investitionsbank des Landes
Brandenburg
Company financing and consultation on subsidies and processing grant
applications in Brandenburg.
ilb.de
Landesamt für Gesundheit und
Soziales Berlin (LAGeSo)
One Stop Agency for all licensing and approvals, for questions concerning biomed- berlin.lageso.de
icine, biotechnology and pharmaceuticals and for more general issues connected
with health, disease control and public health in Berlin.
Technologie Stiftung
Brandenburg
The technology Foundation Brandenburg is dedicated to the advancement of sci- ts-bb.de
ence and research, especially in the field of innovative technologies.
Technologiestiftung Berlin
The Technology Foundation Berlin is a public private partnership in the German tsb-berlin.de
capital region to develop science and industry networks for technology transfer, joint
projects, and regional innovation strategies.
ZAB Zukunftsagentur
Brandenburg
The Brandenburg Economic Development Board functions as a one-stop agency for zab-brandenburg.de
all kinds of business support services.
ZAK Zentrale Anlauf- und
Koordinierungsstelle
Senatsverwaltung für Wirtschaft,
Technologie und Forschung
Helps you find your way through the Berlin administration. Supports complex urban berlin.de/sen/wirtschaft/zak
development policy and investment projects.
Advance Pharma GmbH
Contract manufacturer of solid drugs.Galenic development and admissions, analyt- advance-pharma.eu
ics and microbiology, coating and granulation (organic and aqueous), compacting,
packaging.
ALPHAMADE GmbH
Customized formulations as medications: parenteral feeding, intradialytic parenteral alphamade.de
feeding, omega-3 fatty acids, cytostatics.
AstraZeneca
We are a global innovation-driven biopharmaceutical company specialising in the astrazeneca.com
discovery, development, manufacturing and marketing of prescription medicines that
make a meaningful difference in healthcare. We operate in over 100 countries and
our medicines are used by millions of patients worldwide. AstraZeneca was formed
on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC
of the UK – two companies with similar science-based cultures and a shared vision
of the pharmaceutical industry.
Bausch & Lomb Dr. Mann
Pharma
Bausch & Lomb is the eye health company dedicated to perfecting vision and en- bausch-lomb.de
hancing life for consumers around the world. Core businesses include soft and rigid
gas permeable contact lenses and lens care products, and ophthalmic surgical and
pharmaceutical products.
Bayer Pharma Aktiengesellschaft Bayer Pharma is one of the ten largest specialty pharmaceutical companies in the bayerhealthcare.com
world and the company's goal is a leading market position in each of its specialist
fields. With its distinctive expertise in research, the company develops new medicines and therapies which make an essential contribution toward improving patient's
quality of life.
42
BERLIN-CHEMIE
Aktiengesellschaft
BERLIN-CHEMIE is a German subsidiary of the MENARINI Group. The company, berlin-chemie.de
which was formed in 1886 and is headquartered in Florence, was developed over
the generations to become a global, owner-managed pharmaceutical company. Research is centred on the development of innovative drugs for the following areas:
inflammatory diseases and pain, cardiovascular diseases, oncology, viral disease.
Chemisch-pharmazeutisches
Labor, Rolf Sachse GmbH
CPL S: Custom synthesis development of active pharmaceutical ingredients (API’s), cpl-sachse.de
Contract manufacture of active pharmaceutical ingredients from laboratory to kiloscale, Pharmaceutical analysis.
Daiichi Sankyo
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. daiichisankyo.com
We provide innovative products and services in more than 50 countries around the
world. With more than 100 years of scientific expertise, our company draws upon
a rich legacy of innovation and a robust pipeline of promising new medicines to
help patients. Through the outstanding knowledge and commitment of our 30,000
employees worldwide, we create innovative new and generic medicines, and new
methods of drug discovery and delivery. We share a passion for innovation, as well
as compassion for the patients around the world who are in need of our medicines.
Dr. Kade Pharmazeutische Fabrik The company’s activities concentrate on the production and marketing of drugs in kade.de
the fields of gynecology, proctology, pain relief/ rheumatism and urology. The potenGmbH
tial of proven drugs is expanded systematically by galenic developments to produce
innovative products.
Haupt Pharma AG
With&nbsp,nine production sites Haupt Pharma is one of the leading contract man- haupt-pharma.de
ufacturers for pharmaceutical products in&nbsp,the world&nbsp,today.&nbsp,About
2.000&nbsp,employees produce for an established clientele of more than 200 important international pharmaceutical companies, amongst which 15 of the international TOP 25.
Heyl chemisch pharmazeutische
Fabrik GmbH & Co. KG
HEYL is an independent, entrepreneurial family business that has its headquarters in heyl-berlin.com
probably the liveliest German metropolis, Berlin, since its establishment in 1926. In
cooperation with our international subsidiaries, the main focuses of our work are the
Regulatory Affairs and marketing of medicines as well as the sale of active pharmaceutical ingredients (API's) and special chemicals.
Klosterfrau Berlin GmbH
For more than 175 years Klosterfrau has been developing, manufacturing and mar- klosterfrau.de
keting pharmaceutical products. The profile of traditional yet modern natural medicines has grown significantly in recent times. Based on the latest scientific discoveries combined with the development of new markets, the range is constantly being
expanded with innovative products.
medphano Arzneimittel GmbH
medphano Arzneimittel in Rüdersdorf stands for proven and cost-effective phar- medphano.de
maceutical preparations. Main products are analgesics/anti-rheumatics, antibiotics,
dermatics, diuretics, drugs to stimulate blood circulation, drugs for treatment of gastro-intestinal disorders, vitamins, expectorants, lipid-lowering agents, ophthalmics,
cosmetics, food supplements, diet foods and foods.
MUCOS Pharma GmbH & Co.KG
As a specialist in enzyme preparations Mucos supplies a steadily growing market mucos.de
with specific and variably dosed enzyme combinations. The company leads the
world market in oral enzymes for therapeutic purposes.
Pfizer Pharma GmbH
Pfizer is the world's largest research-based biomedical and pharmaceutical com- pfizer.de
pany.
Pharma Action GmbH
Pharma Action has extensive expertise in global pharmaceutical marketing and man- pharma-action.com
ufacturing since 1988 and offers cutting edge API solutions to the pharmaceutical
industry in Europe and abroad.
PharmaMar GmbH
PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in pharmamar.com
discovering, developing and marketing marine-based drugs to treat cancer. Yondelis® is the first marine-based antitumour drug. PharmaMar has four other compounds
in clinical development: Aplidin®, Zalypsis®, PM01183 and PM060184. PharmaMar
also has a rich pipeline of pre-clinical candidates and a major R&D programme.
PharmaMar GmbH, the German subsidiary, was officially established in November
2013 in Berlin.
Piramal Imaging GmbH
Piramal Imaging is a start-up business within the Life-Science division of the Mum- imaging.piramalenterprises.
bai-based Piramal Enterprises Group. The company is dedicated to the clinical re- com
search & development and the global commercialization of Nuclear Medicine / Molecular Imaging products for detection, characterization and monitoring of disabling
and life-threatening diseases in neurology, oncology and the cardio-vascular space.
Sanofi-Aventis Deutschland
GmbH
Sanofi-aventis is a leading global pharmaceutical company based in Paris and oper- sanofi-aventis.de
ating in over 100 countries. R&amp,D teams work on a global approach to patients,
offering innovative therapeutic strategies in thrombosis, cardiovascular diseases,
diabetes, vaccines, oncology, the central nervous system disorders and internal
medicine.
Shire Deutschland GmbH
Shire’s strategic goal is to become the leading specialty biopharmaceutical compa- shire.de
ny that focuses on meeting the needs of the specialist physician. Shire focuses its
business on attention deficit and hyperactivity disorder, human genetic therapies and
gastrointestinal diseases.
43
Spreewälder Arzneimittel GmbH
Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food spreewaelder-arzneimittel.de
supplements, diet foods and cosmetics in liquid, semi-solid and solid administration
forms.
Steiner & Co. Deutsche
Arzneimittelgesellschaft mbH &
Co. KG
Production and marketing of pharmacy and prescription drugs, particularly plant- steinerarznei-berlin.de
based drugs (tranquillizers, rheumatism drugs, bile duct and gastro-intestinal as well
as gynecological and urological drugs), analgesics and mineral preparations.
Steripharm Pharmazeutische
Produkte GmbH & Co. KG
Production and marketing of folic acid products.
Takeda GmbH
Takeda is Japan´s and Asia´s largest pharmaceutical company and among the lead- takeda.de
ing global companies of its branch, represented in more than 70 countries. Takeda
committed itself for a better health care of patients all over the world by innovations
in medicine. Its therapeutical core areas are metabolic, cardiovascular, inflammatory,
immune and respiratory diseases, diseases of the central nervous system, oncology,
gastroenterology and pain.
Teva GmbH
Teva in Germany is the leader in generics and an expert in innovative brand busi- teva.de
ness. The German headquarter is located in Ulm. Patent-protected medicines from
the fields of neurology, oncology, pain management and respiratory diseases are
marketed by Teva Specialty Medicines in Berlin. Teva Specialty Medicines’ primary
area of success is neurology. The first product to be come from the company's own
development facility contains the active ingredient glatirameracetate and is the market leader among drugs used to treat multiple sclerosis. Another product from Teva’s
own research laboratories, is a standard in the treatment of Parkinson’s disease.
steripharm.de
Contract Manufacturers
Advance Pharma GmbH
Contract manufacturer of solid drugs.Galenic development and admissions, analytics advance-pharma-berlin.de
and microbiology, coating and granulation (organic and aqueous), compacting, packaging.
ALPHAMADE GmbH
Customized formulations as medications: parenteral feeding, intradialytic parenteral alphamade.de
feeding, omega-3 fatty acids, cytostatics.
Ayanda GmbH & Co. KG
Ayanda is an innovative business partner and manufacturer of consumer ready phar- ayanda.com
maceuticals and food supplements. In Pritzwalk, Brandenburg, the company has a
pharmaceutical soft gel encapsulation plant.
Chemisch-pharmazeutisches
Labor, Rolf Sachse GmbH
CPL SACHSE offers: Custom synthesis development of active pharmaceutical ingredi- cpl-sachse.de
ents (API’s); Contract manufacture of active pharmaceutical ingredients from laboratory to kiloscale; Pharmaceutical analysis.
Haupt Pharma AG
With nine production sites Haupt Pharma is one of the leading contract manufacturers haupt-pharma.de
for pharmaceutical products in the world today. About 2.000 employees produce for an
established clientele of more than 200 important international pharmaceutical companies, amongst which 15 of the international TOP 25.
Pharma Action GmbH
Pharma Action has extensive expertise in global pharmaceutical marketing and man- Pharma-action.com
ufacturing since 1988 and offers cutting edge API solutions to the pharmaceutical industry in Europe and abroad.
Spreewälder Arzneimittel GmbH
Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food spreewaelder-arzneimittel.
supplements, diet foods and cosmetics in liquid, semi-solid and solid administration de
forms.
analyze & realize ag
analyze & realize ag is a leading CRO and consulting firm, which primarily give com- analyze-realize.com
plete advice and guidance to companies in the natural products sector.
Allied Clinical Management
GmbH
The CRO has broad experience in monitoring and managing phase I to phase IV clin- allied-clinical.com
ical trials including advanced therapy medicinal product (ATMP) trials as well as in
accompanying and conducting medical device trials and post-marketing surveillance.
Assign International GmbH
Assign International in Berlin is part of the Assign Group, a mid-sized full-service CRO assigngroup.com
with six offices in five countries.Our expertise meets development requirements of
pharmaceutical and biotechnological industries. We manage clinical trials from study
set-up to final clinical report.Our services, among others, comprise Data Management
and Biostatistics, integrated EDC-Systems, Pharmacovigilance, Protocol Writing, Laboratory Services and Quality Management.
BLS Preclinical Services
BLS Preclinical Services is a contract research organization (CRO) located in Berlin. bls-germany.com
BLS provides a range of highquality and integrated preclinical services in animal models. Through our highly skilled scientific partners we provide a “one-stop” service and
tailored solution. We take the time to understand your business needs and provide comprehensive tailored solutions either in-house or in co-operation of our network. We are
backed by a highly skilled scientific team with a wealth of experience in all disciplines
of preclinical development.
44
CBR Biotech Strategies GmbH
CBR International Corporation is a global, full-service product, clinical, and regulatory cbrintl.com
compliance development group dedicated to providing comprehensive consulting services. We understand commercial pressures and regulatory constraints of biopharmaceutical product development and offer full support and guidance to all of our clients.
Our experienced staff and consulting affiliates offer detailed and strategic services
to members of the biotechnology, pharmaceutical, and device industries worldwide.
Charité Research Organisation
GmbH
Based in Berlin, the Charité Research Organisation (CRO) was founded in collaboration charite-research.org
with Berlin‘s famous Charité University Hospital. This relationship fosters a level of cooperation with centers of clinical excellence that we think is unique in the industry. The
CRO offers a whole new approach to the concept of partnering with centers of clinical
excellence to facilitate access to patients, clinical expertise and specialist methodologies in support of early clinical development programs.
Cooperative Clinical Drug
Research and Development
(CCDRD) AG
CCDRD is an independent contract research organization (CRO). CCRDR is dedicated ccdrdag.com
to offer creative and innoative full service from planning to market authorization to its
customers in the pharmaceutical, biotechnological and medical device industry.
CSG Clinische Studien
Gesellschaft mbH
Since its foundation in 1998, the CSG Clinische Studien Gesellschaft mbH has focussed csg-germany.com
on aligning clinical research with public health demands, with special attention to facilitating access by physicians and patients to clinical studies.CSG cooperates closely
with the largest research institute for public health in Germany, the IGES Institut.
Dr. Notghi Contract Research
Dr. Notghi Contract Research GmbH is a service provider for large, medium and small- notghi.com
sized companies in the pharmaceutical, generics and biotechnology industries. We
support and advise you in the conduct and management of national and international
projects.
Klinische Forschung Berlin GbR
Klinische Forschung Berlin is a study centre that implements clinical studies from klinische-forschung-berlin.
phases IIA to IV for the pharmaceuticals industry.
de
Klinische Forschung Gruppe
Nord GmbH
The Klinische Forschung Gruppe Nord (Clinical Research Group North) is a network kfgn.de
of independent investigator institutes with five centres in Northern Germany, two of
them in Berlin.The Klinische Forschung Gruppe Nord has carried out trials with up to
250 patients. Phase II and III studies are the core competence. The test centres have
altogether 30 overnight accommodation places for phase I and IIa studies.
Lampe & Company
GmbH & Co. KG
Lampe & Company is a consulting firm specialized in multidimensional analysis of lampeandcompany.com
biomedical literature for evidence-based decision making. Our team of experts combines industry expertise with our unique L-Matrix Method and exclusive L&C relational
database to deliver critical information to leading decision makers of pharmaceutical,
life sciences, and medtech companies.
MEDIS RESEARCH GROUP
MEDIS RESEARCH GROUP is a partnership of clinical research services providers with medis-research.com
a joint mission to combine clinical research expertise and provide complete service
solutions across all stages of the clinical development process.
OSMUNDA Medical Device
Service Group
OSMUNDA is the largest Chinese clinical trial CRO and service provider for the medical osmundagroup.com
device and in-vitro diagnostic industry. Over 2000 international clients have entrusted
our expertise in regulatory affairs, clinical trials and industrial distributor/supplier resources to achieve their business goals.
PAREXEL International GmbH
The German subsidiary of the US clinical research organization PAREXEL employs parexel.com
more than 1,400 people in Berlin. In two units with a 160-bed capacity (incl. 8 sleep lab
beds) and an annual enrollment of approximately 2,500 volunteers in Berlin, more than
75 clinical studies are performed each year.
PharmaLex GmbH
PharmaLex is one of the leading service providers in the International pharmaceutical pharmalex.com
business. The company is dedicated to the development, registration and marketing
authorization, market access and product maintenance of medicinal / biotechnological
products and medical devices, worldwide. The corner stones of PharmaLex’ successful
co-operation with companies of all sizes and specializations are very high quality of
work, reliability, efficacy, flexibility and anticipatory strategic planning.
Sacura GmbH
Sacura is a full-service contract research organization granting a high level of quality sacura-cro.com
(FDA approved), flexible structures and qualified staff.
WITEGA Laboratorien BerlinAdlershof GmbH
WITEGA Laboratorien Berlin-Adlershof GmbH is a medium-sized company specializing auftragssynthese.com
in the realization of organic customer syntheses. Our customers are companies from
the chemical and pharmaceutical industries as well as from other technology fields. The
main focus of our activities is the lab-scale custom synthesis of organic building blocks,
intermediates and target structures and of isotope-labeled compounds (D, 13C, 15N)
for chemical and pharmaceutical research and development. The company is also a
supplier of analytical standards for residue analysis (especially in veterinary medicine).
45
Biotech Companies
3B Pharmaceuticals GmbH
3B Pharmaceuticals GmbH (3BP) is a privately held pharmaceutical R&D company 3b-pharma.com
based in Berlin, Germany. The company is dedicated to the development of peptide-based pharmaceutical and diagnostic products. 3BP is pursuing projects in hemophilia and nuclear medicine.
8sens.biognostic GmbH
8sens.biognostic develops, produces and sells rapid tests (lateral-flow) and ELISAs for biognostic.de
different markets (human and veterinary diagnostics, food control). Our products are
the QuickSens®-tests for h-FABP, TropI, CRP and hs-CRP and the Reader for quantification QuickSens®OMEGA. Development-on-demand, feasibility studies and production-on-demand are also offered.
ABiTEP GmbH
The ABiTEP GmbH is working in development and production of biotechnological prod- abitep.de
ucts for sustainable agriculture. The team of ABiTEP works for development of non
GMO customer specific technologies in laboratory scale and scale up with modern
equipment and Know how. Capacities for fermentation up to 5.000 L, down stream
equipment as well as freeze drier with capacity of 90 L are available for services. A
molecular biology lab is available for basic science.
Accelero Bioanalytics GmbH
Accelero® Bioanalytics GmbH is a biotech CRO focussing on GxP compliant bioanalyt- accelero-bioanalytics.com
ical ligand binding assays. The company supports PK and PD preclinical/ clinical drug
development on microRNA, miRNA, siRNA, aptamers, plasmid APIs, antisense drugs,
as well as peptide hormones, biosimilars, antibody therapeutics, or cell-based therapeutics (ATMP). The Applied Biosystems Viia7 real-time qPCR system with IVD label for
human Dx operates in full compliance to Good Laboratory Practice (GLP).
Acuros GMBH
Development of osmotic micropumps for medical or microfluidic applications.The in- acuros.de
novative technology enables new options in liquid handling – from disposable micropumps for drug delivery to precision micropumps for lab-on-a-chip development.
Adrenomed AG
Development of biologics against severe sepsis.
Aevotis GmbH
The core competencies of aevotis lie in the targeted conversion of simple carbohy- aevotis.com
drate containing substrates (e.g. agricultural by-products, waste streams, inexpensive
sugars) to high-value carbohydrate based products, their characterization, processing
and testing. Marketable products include novel /optimized enzymes, expression systems,&nbsp, specialized biotransformation and down-stream processes, customized
oligomers and polymers for food and non-food uses.
AFOSA GmbH
Development, production and marketing of diagnostics (ELISA kits), primarily for use afosa.com
in veterinary medicine.
Aglycon Mycoton GmbH
Aglycon Mycoton GmbH is active in the research, development and application of bio- aglycon-mycoton.net
polymers as well and their manufacture and the sales and marketing of products based
on these.
AJ Innuscreen GmbH
The AJ Innuscreen GmbH is a young life science company working in the field of bio- aj-innuscreen.de
technology and boosts the life science unit of Analytik Jena AG. Innovative technologies
and products are developed and produced for the isolation and purification of nucleic
acids. Reagent systems for molecular biology, as well as technologies and products
for molecular diagnostics, are also included in the product portfolio. The company is
EN ISO 9001:2008 and EN ISO 13485:2003 + AC:2009 certified.
Alacris Theranostics GmbH is a company based in Berlin specialised in developing alacris.de
new approaches in personalised medicine for cancer patient diagnosis, treatment and
drug stratification. Alacris is applying a systems biology approach that has been developed in the Department of Prof. Lehrach at the Max Planck Institute for molecular
Genetics and is exclusively licensed as ModCellTM to Alacris.
Alcat Europe GmbH
Alcat Europe GmbH is the daughter of the US company Cell Science Systems, the orig- alcat-europe.com
inal developer of the Alcat test technology. The company is specialized to identify intolerant reactions of the leucocytes to foreign substances like foods, drugs or chemicals.
adrenomed.com
Algenol Biofuels Germany GmbH The company focuses on the biotechnological use of cyanobacteria, especially the algenol.com
development and optimization of cyanobacteria for the production of environmentally
friendly biofuels and chemical feedstocks.
ALRISE Biosystems GmbH
ALRISE is a drug delivery company that specializes in the nano- and micro-encapsu- alrise.de
lation of active ingredients. Using its globally patented ImSus® technology, ALRISE are
developing parenteral deposit pharmaceutical forms for proteins, peptides or small
molecules. Customers are mainly large pharmaceutical companies who are developing
improved administration forms for active ingredients whose patents are expiring together with ALRISE as part of their “Product Lifecycle Management”.
Amal Therapeutics S.A.
Amal Therapeutics SA is a Swiss biotech start-up company and spin-off from the Uni- amaltherapeutics.com
versity of Geneva with a subsidy in Berlin. Amal uses its proprietary cell penetrating
peptide platform to develop and progress therapeutic vaccines in oncology.
Amocol Bioprocedures Ltd.
Amocol Bioprocedures Ltd is a life science research & development and manufacturing amocol.com
company headquartered in Germany. Our mission is to supply innovative affinity chromatography media products and protein purification tools for research scientists and
clinical customers in public sector institutes and industry.
AnaKat Institut für
Biotechnologie GmbH
AnaKat Institut für Biotechnologie GmbH has specialized on analytical determination of anakat.de
pharmaceutical ingredients.
46
Biotech Companies
Analyticon Discovery GmbH
AnalytiCon is a biotechnology company focusing on the development of compound ac-discovery.com
libraries consisting of natural product (NP) and synthetic small molecules. As the global market leader in NP small molecule screening compounds, AnalytiCon is the only
company which is able to provide vast collections with completely disclosed structural
information. As a pure compound provider the company is offering its products and
services to the pharmac., chemical, biotech, cosmetical and nutraceutical industry.
Analytisches Zentrum Biopharm
Berlin GmbH
Analytisches Zentrum Biopharm GmbH Berlin is a contract research organization pro- analytisches-zentrumviding services on pharmaceutical analysis and bioanalysis for active compounds in biopharm.de
the dosage form, for the quantitative determination of analytes in a biological matrix
and also the determination of physicochemical parameters of chemicals according
to OECD guidelines. AZB carries out these services in compliance with GLP and GMP
and has the GLP certificate.
AnaTox GmbH & Co. KG
The AnaTox GmbH & Co. KG deals with the development and optimization of analytical anatox.de
methods and devices for HPLC and dissolution.
Anau Berlin-lab GmbH
Development and distribution of lab devices.
ANiMOX GmbH
Development of applications for the use of natural peptide / amino acid mixtures in animox.de
chemistry and biotechnology, f.i. as a scavenger material in formaldehyde bounded
formulations, foaming or hydrophobic Tensid compounds or as a N-source in biotechnological fermentation processes, distribution of a technology for the production of
such basic materials from raw and residual materials.
Aokin AG
Aokin AG is a Berlin biotechnology company that is specialized in the development aokin.com
and commercialization of innovative analytical systems on the base of the rapid kinetic
assay technology. The aokin systems are unique in their precision and operating speed.
Areas of application are food and antibody analytics as well as clinical diagnostics.
We also offer laboratory services in the area of food analytics, Pharmacoanalytics and
chemical synthesis.
ARGUS Umweltbiotechnologie
GmbH
ARGUS is a medium-sized company. Since 1987 ARGUS works on the field of remedi- argus-umwelt.de
ation of contaminated groundwater, soil, waste water and waste air. ARGUS is able to
elaborate a specific remediation program in each different pollution case considering
economic aspects beside ecological aspects. All necessary treatment steps can be
planned and carried out. The combination of microbiological steps with classic processes leads to a successful remediation of complex contamination.
Artemiflow GmbH
Artemiflow is a spin-off from the Max Planck Institute of Colloids and Interfaces (MPIKG). artemiflow.com
By the industrial use of an international patent held by MPIKG, Artemiflow uses a new
process to produce Artemisinin from dihydroartemisinic acid (DHAA). DHAA is available in abundance in the waste of the current production process for Artemisinin.
ASCA GmbH Angewandte
Synthesechemie Adlershof
ASCA is a partner for contract research in the field of medicinal chemistry. The syn- asca-berlin.de
thesis and optimization of lead structures, the development of new active structures
and their check on a laboratory scale are offered. We take a lot of care on working out
the synthetic schemes, rapid preparations and exact analysis of the samples. All our
results are carefully documented for our customers. Access to literature databases and
in-house analytical facilities are available.
Astra Biotech GmbH
Astra Biotech GmbH offers high quality reagents, allergens, antibodies, recombinant astrabiotech.de
proteins, and assays for the determination of hormones, allergies, tumour markers and
infectious diseases. Quality is one of the key cornerstones on which Astra Biotech maintains its reputation and with which we strive to increase customer satisfaction and gain
growing customer loyalty. We take great pride in our highest quality assays, which are all
IVD compliant and therefore suitable for direct, accurate and reproducible diagnostic
purposes, as well as for research.
ATLAS Biolabs GmbH
ATLAS Biolabs GmbH is a leading provider of microarray based genomic services atlas-biolabs.com
such as genome wide gene expression and SNP analysis, CGH analysis and diagnostic
services for registered doctors and hospitals, as well as for pharmaceutical, biotechnological and diagnostic enterprises.
Attomol GmbH Molekulare
Diagnostika
The company’s aim is to develop, produce and distribute medical diagnostics for hu- attomol.de
man medicine in the field of molecular genetics, infectious and autoimmune diseases.
AudioCure Pharma GmbH
AudioCure is focus on the clinical development of drug candidates for neurodegener- audiocure.de
ative diseases with high unmet medical need.
AutoTissue GmbH
The company is engaged in the development, production and marketing of medical de- autotissue.de
vices for cardiovascular surgeons. The products are specially made for the patients and
have less side effects. The first certified product was a pulmonary heart valve (Matrix P)
for the right ventricular outflow tract reconstruction (RVOT). The second product is also
a heart valve which considerably shortens the operation time (Matrix P plus). Meanwhile
a complete glutaraldehyde free valve is available called Matrix P plus N.
Avitop GmbH
Avitop is focusing on probiotics and food concepts with specific health indications. avitop.de
Based on the highest scientific standards, we develop a new generation of probiotics
and food with unmet specific functions.We deliver the food industry with new and specific solutions for actual and future health challenges facing modern society.
47
Biotech Companies
Bbi-biotech GmbH
In the focus of the activities of bbi-biotech lie systems for the sterile sampling from bbi-biotech.com
bioreactors for all applications in the biotechnology, pharmaceutical, food, cosmetics
and chemical industry. In addition, bbi-biotech develops components - in especially
disposable ones - for the preparation of a new generation of fermentors and bioreactors and offers consulting and planning services for biotech projects, its implementation
and services.
BEB BioEnergy Berlin GmbH
Planning, Design, Construction, Supervision and Implementation of Biogas/Hydropow- bebgmbh.de
er plants, Preplanning, Feasibility Studies and Research activities in the field of renewable energies, Optimization of the process in existing biogas plants.
BG Berlin-Genetics GmbH
BG Berlin-Genetics GmbH is a new provider for genetic diagnostics and consulting in bg-berlin-genetics.de
genetic diagnostics. We are a team of experienced human geneticists and have worked
for many years in the field of human genetic science and human genetic diagnostics.
Our aim is the development of innovative cooperation concepts, to connect classical
patient-based medical care centers with modern technology-based service centers.
In future, these cooperation forms will enable efficient, high quality, and patient-based
genetic diagnostics.
Bioanalyt GmbH
Bioanalyt develops and distributes the worldwide first easy-to-use and portable test kits bioanalyt.com
for the analysis of vitamins and micro nutrients. The iCheck-iEx test kits enable food producers, food authorities and NGOs to monitor their ongling food programms more efficiently and at low-cost. The company was founded in 2006 by Prof. Dr. F. J. Schweigert
as a spin-off of the University of Potsdam. Read more on our website bioanalyt.com.
Bioassays GmbH
Service related to the development of medical in vitro-diagnostic products. Basic sci- bioassay-online.de
ence to clinical development. Profiling of biomarkers in clinical trials.
Biochrom AG
Biochrom is Germany’s largest manufacturer of cell culture products (media, sera, and biochrom.de
others) and sterile liquids. They are distributed to universities, industrial cell culture
laboratories and industrial manufacturers. Service is of special significance for users
of cell cultures. Special media developments and production optimizations are offered.
BIOCYC Gesellschaft für
Biotechnologie und Recycling
mbH & Co.KG
Production of bio-chemicals, peptides, in vitro-diagnostics, test-kits. Development of quartett.com
consumer service for peptides and biochemicals.
BioGenes GmbH
BioGenes is a full service immunoassay and antibody (monoclonal and polyclonal) biogenes.de
development company with outstanding problem solving capabilities specializing in
challenging projects that are carried out by an exceptionally experienced and interdisciplinary team.
Bioline GmbH
Our mission is to provide customers with a range of products which are fast and easy bioline.com
to use, guaranteed to work and developed by scientists who understand what our customers are trying to achieve so they can focus on their scientific goals. Bioline reagents
are used by molecular biologists and other research scientists to perform test-assays
and research in many fields from medical, biotechnology and marine biology.
BioMedion GmbH
IT-Service for all GxP-Regulatory Tasks Data- and Document Management, Long-Term- biomedion.com
Archiving and Digital Signature, SOP-Management, CAPA, Raw Data Management,
Consulting for Validation of Computerized Systems according to GAMP4/5.
Biopract GmbH
Service and Additives (enzymes, trace elements, microbes) for biogas and waste wa- dsmbiogas.com
ter sludge treatmentEnzyme analysis in agriculture industry Contract reserach feed
additives.
Biorefinery.de GmbH
Based on main precursors of plants, carbohydrates in kind of sugar, starch and cel- biorefinery.de
lulose, and proteins, the biorefinery.de company has developed four complex product
lines (Biorefinery systems) which leads to a great number of valuable products with the
help of chemistry and biotechnology.
BioRepro GmbH
BioRepro is the first pharmac. company, whose core competency is the breeding of biorepro.de
leeches under controlled laboratory conditions for medical therapies. We concentrate
on the establishment of GMP breeding procedures and will be able to provide leeches
with standardized quality while equally allowing scalability to supply medical demand.
Additionally, through the re-initiation of fundamental research, we will gain deeper understanding of further potential in medical and cosmetic treatment areas.
BioS Biotechnologie Schönow
GmbH
Embryo transfer and associated biotechnologies in animals. Service, training and re- bios-schoenow.de
search in this field.
BioSilta Europe GmbH
BioSilta is an international company that specializes in advanced tools for microbial biosilta.com
cell cultivation, protein production, enzyme screening and food spoilage testing. The
patented EnBase® technology resembles fed-batch mode and provides a cultivation
environment with glucose-control, pH maintenance and inhibition of growth-limiting
metabolites without the need for traditional mechanical pumps. EnBase® is provided in
ready-to-use liquid or tablet products. BioSilta specializes in small-scale cultures and
it?s products offer customer solutions from multi-well plates to small-scale bioreactors.
Learn more about our products and applications at biosilta.com.
BIOSYNTAN Gesellschaft für
bioorganische Synthese mbH
BIOSYNTAN offers the custom synthesis of standard peptides, the synthesis of mod- biosyntan.de
ified peptides (e.g. glyco- and phosphopeptides, dye labeled peptides) and hapten
modifications for the conjugate synthesis. In cooperation with BIOGENES GmbH Berlin
we offer poly- and monoclonal antibodies.
48
Biotech Companies
Biotech-Laboratorium für
Environment BLE GmbH
Development of detection systems which are able, economically and rapidaly, to detect mobiclup.de
oil contaminations and industrial oil waste, in soil and in water and their biological depletion. The BLE GmbH is concerned with the biological degradation of oil contaminations and the development of a set of bio-preparations consisting of different bacterial
strains which break down oil.
biotechrabbit GmbH
biotechrabbit GmbH is determined to offer the newest and best life science products biotechrabbit.com
and innovative solutions to scientists leading the fight againstdisease and fueling our
lives with innovations. We supply ultra pure enzymes and high-quality antibody services for diagnostics and a life science product portfolio(including reagents for PCR
and nucleic acid purification)for molecular biology and proteomics. The biotechrabbit
advantage is our combination ofpassion for excellent research with the agility of true
entrepreneurship.
BIOTECON Diagnostics GmbH
BIOTECON Diagnostics has been well known as a qualified partner in the field of mo- bc-diagnostics.com
lecular and microbiology for the last 13 years. We focus on development, production
and marketing of PCR-based rapid detection systems. BIOTECON Diagnostics offers
solutions for the food and beverage industry as well as for producers of pharmaceuticals and cosmetics.
BioTeZ Berlin-Buch GmbH
Services (Custom DNA and RNA Oligonucleotide synthesis, Immuno affinity columns) biotez.de
- Development of Enzyme Immunoassays, e.g. for Therapeutic Antibodies- Bio Conjugates - Immobilization of Bio Molekules for better Signalling-R&D (Aptamer).
BIOWORX -BiotechnologielaborThomas Grimm
BIOWORX offers services in the fields of contract research for customer-specific Bio- bioworx.de
transformations, the screening, isolation and production of Biocatalysts from microorganisms and plants and the bioanalytic syntheses. Further organic compounds and
metabolites will be synthesized with enzymes for customer in kg scale.
BiRDS Pharma GmbH
BiRDS Pharma GmbH, integrated into the BDD/CCDRD group, provides services in the birdspharma.com
field of drug development to pharmaceutical and biotech companies, including management of drug development projects as well as consulting services. The company
also pursues own drug development projects based on intellectual property generated
within BDD/CCDRD group, with a focus on drug candidates derived from Atomic Substitution Technology (AST).
Blue Biolabs GmbH
Blue Biolabs is a spin-off company from the TU-Berlin, which specialises in the devel- bluebiolabs.de
opment of products and services in the field of environmental analysis using methods
of microbiology and molecular biology.
Botiss medical AG
Botiss biomaterials is a privately owned biotech company, headquartered in Berlin. botiss.com
botiss is the leading German specialist for dental bone and tissue regeneration (BTR).
We focus on the development of innovative regenerative materials and clinical marketing / distribution in over 50 countries world-wide. The botiss subsidiary Cell+Tissue
Bank Austria is a leading European manufacturer of allogenic materials for hard tissue
regeneration.
BST Bio Sensor Technology
GmbH
BST develops and produces biosensors to provide high quality analysis at moderate bst-biosensor.de
prices. In 1982 BST brought on the market the first multi-way biosensor based blood
glucose analyzer in Europe and is since then market leader in Europe. Today BST sells
more than 60.000 sensors a year. Since 2008 BST is besides biosensors also manufacturer of POCT and laboratory instruments.
Caprotec bioanalytics GmbH
Caprotecs Capture Compound Mass Spectrometry (CCMS) Technology allows sepa- caprotec.com
ration and isolation of proteins based on functionality. For many applications, CCMS is
clearly superior to conventional methods - thus addressing an unmet need in the proteomics research community. The company is commercializing the CCMS technology
through ImproMed projects with pharmaceutical and biotechnology companies. The
focus on these collaborations is on investigating mechanisms of drug action (MoA)
and identification of on- and off-target proteins to understand potential adverse effects
of drug candidates on a molecular level. This can be easily carried out in the lead
optimization process, or even earlier to increase the probability of success later on in
the clinic.
Capsulution Pharma AG
Capsulution Pharma AG develops innovative nano- and micron-sized capsules. The capsulution.com
company applies its worldwide-patented so-called LBL-Technology®. Based on their
minute size, their functionality and their highly reproducible production process the
capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules (500 nm to 50 µm) can be made to function in a manner to suit the
intended application, and can be given the appropriate biochemical, electrical, optical
and magnetic properties as required by the customer.
Celares GmbH
Specialist for Drug Delivery of peptides/proteins by using PEGylation. Modification of celares.com
Biopharmaceuticals with polyethylene glycol in order to substantially improve pharmacological properties. Offers the unique CelaSYS-PEGylation technology, which is
patented by celares. CelaSYS: non-dispersed, highly branched polyethylene glycol
based reagents. Additionally celares offers customized PEGylation solutions as well as
synthesis of customized PEG-reagents.
Cell Medica GmbH
Cell Medica develops, manufactures and markets personalized cellular immunothera- cellmedica.co.uk
peutics for infectious disease and cancer.
49
Biotech Companies
CellServe GmbH
CellServe is a service provider for research groups in regenerative medicine and fills an cellserve.de
important gap in the conversion of applied treatment concepts from research into marketable products. Furthermore CellServe develops own innovative cell-based products
for cardiology and uses novel cardiac derived cells ("From the Heart to the Heart") for
the treatment of chronic heart failure.
CellTrend GmbH
Celltrend is certified according to ISO 9001, ISO 13485 and GMP Cell culture systems celltrend.de
for research on active substances (bioassays, preclinical research, for quality control)
Development and production of antibody-based detection systems (ELISA) Chemosensitivityassay for optimisation of chemotherapy (tumor patients).
Chemicell GmbH
Chemicell develops and produces magnetic, fluorescent and coloured nano- and mi- chemicell.com
croparticles, reactive fluorescent dyes and special chromatography-materials for the
separation or detection of cells, bacteria, viruses, proteins or DNA/RNA and new gene
transfer systems.
Chipron GmbH
Chipron GmbH specializes in production and distribution of array based detection sys- chipron.com
tems for DNA/pathogens.
CHIRACON GmbH
chiracon is a qualified partner to develop chiral intermediates at a constant high quality chiracon.de
for innovative drugs regarding economic, environmentally acceptable and scaleable
aspects. We offer support through expert knowledge and key technology to meet your
increasing needs. Our core competence is chirality. In addition we have a broad variety
of chiral building blocks as an inhouse raw material source for high-level API production
and development.
CMZ-Assay GmbH
Marketing of diagnostic reagents for measuring concentrations of proteins, hormones cmz-assay.com
and their isoforms, exclusively for research purposes.
co.don® AG
co.don® AG is one of the leading biopharmaceutical companies in the area of Regen- codon.de
erativeMedicine/Tissue Engineering. Since 1997, co.don® AG has developed, manufactured anddistributed human Tissue engineering therapeutics for the regeneration of
articular cartilage and intervertebral discs.
CONGEN Biotechnologie GmbH
CONGEN is specialized in food testing by molecular analytics based on DNA and RNA congen.de
detection. CONGEN has been a pioneer for over a decade in the development and
application of food and feed analytics by real-time PCR. The methods are available
as complete analytic kit as well as a Service. Our mission is to serve the food industry
with an excellent service and with standardized and reliable test kits in order to realize
highest possible food safety and food quality.
Cyano Biotech GmbH
Cyano Biotech identifies and characterizes natural products from cyanobacteria and cyano-biotech.com
optimizes their pharmacological activities employing a biocombinatorial approach. The
company conduct further development of identified lead structures till the preclinical
phase.
DendroPharm GmbH
DendroPharm, a spin-off from the Free University of Berlin, develops innovative cus- dendropharm.de
tomized to drugs nanocarriers, which allow active pharmaceutical ingredients more
focused and objective to bring: in tumor tissue, cartilage or into the skin.
DexLeChem GmbH
We are experts in the reactivation of complex chiral catalysts. For the first time the dexlechem.com
unmodified homogeneous catalyst can be re-used repeatedly thanks to our innovative
water based process. Supported by quantum chemical analysis we are able to simulate
catalytic cycles. Combined with our special knowhow this enables us to find the best
solvent system for our customers. By using this new resource-efficient reaction route our
customers – manufacturers of active pharmaceutical ingredients (APIs) and fragrances
– gain two advantages: reduction of production costs and a more sustainable process.
Diaglobal GmbH
Development, production and distribution of in vitro-diagnostics for analytical purpose diaglobal.de
and the distribution of medical products.
DIZG Deutsches Institut
für Zell- und Gewebeersatz
gemeinnützige GmbH
DIZG German Institute for Cell and Tissue Replacement engages in cell and tissue dizg.de
preservation as well as in cell and tissue replacement, and provides tissue preparations
of human origin to clinics, teaching and research organisations. Further service is culturing of skin cells (keratinozytes) for serious burns and other skin defects not healing
well or affecting large areas. DIZG supplies cell cultures to help avoid experimentation
with animals e.g. in the cosmetics industry.
Dr. Götz Verfahrenstechnik
Biotechnik Umwelttechnik
Contract research and contract manufacturing using bacteria, yeasts and fungi.
Dr. Lerche KG
Innovative company engaged in development, production and marketing of special- lerche-biotec.com
ized microcapsules for bio- and medical technology - Development and production of
novel DNA-Purification-Kits with proprietary technology - Production and marketing of
microcapsules (LUMiTainer), microbeads and cell based sedimentation standards for
blood analysis (Sedi-Val ESR standards) - Encapsulation of cells - Contract analysis for
characterization of microcapsules, porous membranes and hollow fibres.
Dr. Otto GmbH
Handling with research and development of ecological products its process of devel- dr-otto-gmbh.de
opment also its production and marketing - Production and refinement of plantingredients - Operate an analytical laboratory of renewable resources and chem. Analysis.
Dr. Rölleke Labor für Genetische
Analytik GmbH
Dr. Roelleke is specialized on the identification of microorganisms, particularly in the dr-roelleke.de
area of food safety. Furthermore, Dr. Roelleke is authorized expert on paternity tests for
courts and the private sector.
50
drgoetz.de
Biotech Companies
Drug Response Dx GmbH
DRDx makes drug response predictable: Challenge and necessity of personalized drdx.de
medicine and individualized therapies demand for convincing and reliable companion
diagnostics. The first field of activity of DRDx is Rheumatoid Arthritis (RA). The goal
of our company is the technical and clinical validation of an IVD test kit for the reliable
prediction of therapy response to TBAs ahead of treatment.
E.R.D.E.-AAK-Diagnostik GmbH
E.R.D.E.-AAK-Diagnostik GmbH is a laboratory that offers antibody testing for com- aak-diagnostik.de
mercial purposes.
EMP Biotech GmbH
Production of fluorescent dyes and chemiluminescent reagents. Contract chemical empbiotech.com
synthesis of small molecules. Contract labeling and purification of proteins, antibodies
and oligonucleotides. Production of size-exclusion gels, columns and filter plates. Production of high quality reagents for DNA synthesis.
Epigenomics AG
Development and commercialization of innovative molecular diagnostic test products epigenomics.com
based on DNA methylation for cancer screening and for cancer specialty applications.
Epinamics GmbH
Epinamics GmbH, a newly established Berlin based pharmaceutical research and epinamics.com
development dedicated company, is owner of a proprietary film forming formulation
technology platform, the ?Invisible Patch? system. The system is offering a broad basis
for the development of formulations for treatment of dermatological diseases as well as
for the development of transdermal systems.
Epiontis GmbH
Establishing methylation fingerprinting as Gold Standard for quality control in Regener- epiontis.com
ative Medicine and Immunomonitoring.
Epo Experimentelle
Pharmakologie & Onkologie
GmbH
The pharmaceutical and oncological testing of new drugs or treatment concepts for epo-berlin.com
cancer is a specialized market segment. Using the equipment available, all experimental techniques can be carried out in first-rate quality. That means that EPO is an attractive partner for the drug development section of large pharmaceutical companies, for
partners from the Biotech industry and for research institutions.
Eternygen GmbH
Eternygen is a Berlin based start up founded in June 2012 focusing on research, de- eternygen.com
velopment and marketing of innovative drugs using a network of renowned scientists
and contract research organizations. The main focus of Eternygen´s development and
core competences of its founders are research and development of new drugs for
dietary-related metabolic diseases with dramatically increasing prevalences in the last
decades.
Eurovir Hygiene-Institut/Dr.
Thraenhart
Laboratory service for testing the efficiency of products against viruses (virucides) and eurovir.de
of processes for inactivating or eliminating viruses (virus safety).
EVESTRA GmbH
EVESTRA is a newly founded biotech company focusing on developing female health evestra.com
products. The companies expertise resides with steroid chemistry and biology. EVESTRA’s product pipeline includes products for contraception, hormone replacement therapy, gynecological disorders and hormon dependent cancers.
F.A.T. Forschungsinstitut für
Antioxidative Therapie GmbH
Measuring instruments and kits for evaluating the antioxidant properties and the degree antioxidant-research.eu
of oxidative damage in biological substrates.
Fermtec GmbH
Development of non-alcoholic beverages, beers and beer mix beverages, lactic acid fermtecgmbh.de
fermentation, innovative foods and beverages and auxiliary substances for the food
industry.
FILT Lungen- und
Thoraxdiagnostik GmbH
Development of innovative, non-invasive diagnostic methods in the area of respiratory filt.de
diseases and allergies.
Formula GmbH
Galenical development of liquids and solid formulations Lyophilization Technolgy also formula-pharma.de
apllicable for biochemical products Granulation, drying and coating using fluid bed
drying-technology, tabletting Development and validation of analytical methods including UPLC Stability testing (ICH / GMP related to on going) Import of medicinal poducts
from non-EU-countries, manufacturing, quality control (re-test) and release for market
in accordance with §16 AMWHV for medicinal products and clinical supplies GMP-certificat / Manufacturing license in accordance with §13 AMG.
G&Life SpA
G&life provides personalized strategies based on genetics. The life-science company glifecompany.com
is made up of a multi-disciplinary team combining expertise in genetics, nutrition, sport
and engineering to develop products and services aimed at improving the quality of
life.
GA Generic Assays GmbH
Development, manufacturing and distributing of in vitro-tests, focussing on autoimmune genericassays.com
diseases, hereditary and infections diseases.
Gene Analysis Service GmbH
Gene Analysis Service is specialized on genetic testing of a number of rare hereditary gene-analysis-service.de
diseases and provides nucleic acid based molecular biological services like PCR and
custom DNA sequencing for healthcare providers and research institutes worldwide.
GenExpress Gesellschaft für
Proteindesign GmbH
GenExpress is a flexible company providing services in molecular biology. For over a genexpress.de
decade we have successfully worked for customers in clinical laboratories, research
institutions and the industry. We offer cloning of PCR targets, preparation of synthetic
genes, expression of proteins, evaluation of LightCycler® assays, furthermore production of internal controls and standards for Real Time PCR systems, also cloning, expression and purification of proteins.
51
Biotech Companies
GILUPI GmbH
GILUPI is a medical diagnostics company with an initial focus on the prenatal and can- gilupi.com
cer market. The company is developing an innovative new diagnostic product based
on nanotechnology. Our goal is to catch specific cells, which can be found only in very
low concentration in the blood. The first application for our new nanosensor device will
be prenatal diagnoses of chromosomal aberration out of maternal blood. The second
application will focus on the early diagnosis of cancer.
GlucoMetrix PVS GmbH
The GlucoMetrix AG focuses on the early detection and management of diabetes glucometrix.de
mellitus-aftermath. At the foreground of research and development is the enhancing
the quality of life of diabetics. In addition, the life science company develops some
IT-based diagnostic procedures and medical devices as well as biopharmaceuticals
and other highly effective products in order to raise the quality of life of diabetics sustainably.
Glycon Biochemicals GmbH
Production of carbohydrate components used for the synthesis of new pharmaceutical glycon.de
compounds or diagnostics.
Glycotope GmbH
Glycotope is a leading company in glycomics and immunotherapeutics. It has devel- glycotope.com
oped novel therapeutic antibodies and unique platform technologies to optimize the glycosylation of new biological entities. Glycotope Biotechnology, with 25 years of experience in GMP-production, enables us to offer the entire process of biopharmaceutical
development with a dedicated focus on our unrivalled expertise in protein glycosylation
from the gene to production and fill & finish of clinical grade material.
GlycoUniverse GmbH
GlycoUniverse GmbH & Co KGaA is a technology spin-off of the Max Planck Institute of glycouniverse.de
Colloids and Interfaces. Registered on 10th October 2013, the company deals with the
automated development and synthetic production of complex sugars and is seeking
customers and collaboration with leading scientific institutes in Europe and world-wide.
Götz Protein Engineering
Offering a wide range of protein technology up to the final purified protein.
HealthTwiSt GmbH
HealthTwiSt is a service provider for “Genetic Contract Research” in the fields of Func- healthtwist.de
tional Genomics, Epigenetics, Proteomics or Functional Food / Nutriceuticals. In particular, HealthTwiSt is offering access to extensively characterized human subjects and
samples as well as prospective studies in twins, together with know-how in the analysis
of complex genetic traits. Furthermore, database development, data management and
statistical analyses for clinical projects are provided.
HF Biotec Berlin GmbH
Development, selling and operating of digestion plants using liquid substrates of indus- hf-biotec.com
trial and agricultural provenience, Development and operating of combined plants to
upgrade biogas into bio methane useable in public gas grids with parallel production
and selling of high quality PCC, Development of innovative biotechnological processes
and plants.
Hybrotec GmbH
Hybrotec GmbH is specialized in the development of monoclonal antibodies and im- hybrotec.com
munoassays (preferably homogenous assays) as customs service. Our main focus lies
on antibodies binding low molecular weight substances (e.g. toxins, fluorophores, hormones) as well as antibodies against novel proteins.
ICI GmbH
ICI – immunochemical intelligence gmbh – is dedicated to the development and pro- ici-diagnostics.com
duction of innovative immunoassay components and kits for research use. Their goal
is to provide individual solutions, exactly tailored to the client’s needs and to create
lasting relationships by providing outstanding services and high quality products to
demanding clients.
Icon biotech
Icon biotech is an innovative biotechnology company, which uses the extraordinary icon-biotech.com
characteristics of Ciliates for the development of bio-analytical and toxicological model
systems.
IDrug GmbH
IDrug supports business strategies with innovative methodologies in analytical and bio- idrug.de
pharmaceutical chemistry
Ifp Institut für Produktqualität
GmbH
Ifp Institut für Produktqualität is a laboratory and competence centre for state-of-the-art produktqualitaet.com
food, drinking water and pharmaceutical analysis. The accredited and GMP-certified
company focuses on comprehensive services for the food and pharma industry. An
additional core competence of ifp is the development and production of innovative
diagnostics comprising the real-time PCR kits of the brand “mericon” (QIAGEN), vitamin tests in microtiter plate format, enzymatic microtiter plate kits for sugars/acids, and
allergen tests in lateral flow and ELISA formats.
IGV Institut für
Getreideverarbeitung GmbH
The range of services offered by the Biotechnology Division of the private research igv-gmbh.de
IGV GmbH institute is based on 25 years of experience in R&amp,D for the cultivation
of phototropic micro-organisms. Excellent, world-wide contacts to biomass producers,
food producers, to the pharmaceutical and cosmetics and energy industry provide the
fundament for innovative, market-oriented developments. In focus are development of
photo bioreactor technology and active substances from algae.
IKDT Institut Kardiale Diagnostik
und Therapie GmbH
IKDT was founded in August 2002 in Berlin-Steglitz and is one of the leading laborato- ikdt.de
ries on Viral Infections of Heart Muscle Tissue and Dilatated Cardiomyopathy (DCM) in
Germany. IKDT lab is performing a comprehensive molecular diagnostic examination of
endomyocardial biopsies as one of a limited number of specialized cardiological labs
worldwide. Its service enables physicians firstly to start an efficient, pathophysiologically based causal therapy.
52
goetz-protein-engineering.
de
Biotech Companies
ILBC GmbH
Research, consulting, production, trade & services in the areas biology, molecular bi- mobiclup.de
ology and protein chemistry - Expression and production of antimicrobial peptides.
ImaGenes GmbH
RZPD spin-off, today part of Source BioScience plc, a premier service center for ge- imagenes-bio.de
nome research and healthcare in Europe, provides one of the largest clone collections
in the world via its clone search engine GenomeCube®. Certified Service Provider for
illumina Next Generation Sequencing services and comprehensive microarray application on Affymetrix, Agilent, and NimbleGen platforms. ISO 9001:2008 certified.
In.vent DIAGNOSTICA GmbH
in.vent DIAGNOSTICA GMBH is a biomedical company. We are focused on the proj- inventdiagnostica.de
ect-oriented provision, processing and distribution of biological raw material for development and production of diagnostics and control material. We are your reliable
partner for the customised development of assays for medical in vitro-diagnostics.
inbion GmbH
inbion GmbH provides services to support research in the interface between university, inbion.de
students and industry. For companies, we provide the benefit of outsourcing projects
quickly and cost-efficiently to competent teams. Cooperation with research groups in
the university is also facilitated, so that targeted knowledge transfer can take place
here.
Innovative Optische Meßtechnik
GmbH
Fluorescence Assay Solutions and Instrumentation (Microplate Readers).
iom-berlin.de
Institut für Medizinische
Molekulardiagnostik (IMMD)
GmbH
Gene tests for prenatal, predictive and tumor -diagnostics.
immd.de
Institut für Molekular- und
Systemmedizin I.M.S.M. GmbH
Scientific-practical works in the area of System medicine with the purpose of the patenting of new treatment methods, e.g. to the treatment of diabetes. International cooperation in this area.
InterMune GmbH
InterMune is a biotechnology company focused on the research, development and intermune.de
commercialization of innovative therapies in pulmonology and fibrotic diseases. In
pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary
fibrosis (IPF), a progressive and fatal lung disease.
InVivo Biotech Services GmbH
As a contract manufacturing company (CMO) Invivo offers a wide range of services: invivo.de
the development and production of monoclonal antibodies and recombinant proteins
for diagnostic and pre-clinical use (endotoxin-free antibodies and compliant documentation), cell line development and transient transfection. We are an ISO9001:2008 certified company.
InvivoContrast GmbH
InvivoContrast provides globally high quality MRI (Magnetic Resonance Imaging) con- invivoContrast.com
trast agents and professional support for preclinical imaging in academic and commercial institutions.
JPK Instruments AG
JPK Instruments AG is a world-leading manufacturer of nanoanalytic instruments - par- jpk.com
ticularly atomic force microscope (AFM) systems and optical tweezers - for a broad
range of applications reaching from soft matter physics to nano-optics, from surface
chemistry to cell and molecular biology. From its earliest days applying atomic force
microscope (AFM) technology, JPK has recognized the opportunities provided by nanotechnology for transforming life sciences and soft matter research.
JPT Peptide Technologies GmbH
JPT is an ISO 9001:2008 certified provider of innovative peptide products and services jpt.com
and a partner for research projects focusing on the development of novel immune
therapeutics & diagnostics, profiling of various enzyme classes and proteomics. JPT
has developed a portfolio of proprietary technologies and a series of unique products
which support a worldwide customer base. Since 2011 all catalog products such as
peptide microarrays & peptide pools are avalaible through an online shop.
KNAUER - Wissenschaftliche
Gerätebau Dr. Ing. Herbert
Knauer GmbH
KNAUER UHPLC and HPLC systems as well as columns are used in research and knauer.net
development, quality control and production plant laboratories around the world. Customers are typically governmental and industrial organizations as well as universities.
Fields of application are wide-ranging and include pharmaceutical and medical research, analysis of foodstuffs and cosmetics, as well as environmental analysis. With
our biochromatography solutions we focus on high resolution separations.
L.U.M. Gesellschaft für
Labor-, Umweltdiagnostik &
Medizintechnik mbH
Analysis, diagnosis and sensor technology as well as stability, rheology and segrega- lum-gmbh.de
tion behavior of dispersions.
labfolder GmbH
labfolder is a digital notebook and collaboration platform for laboratory research. As a labfolder.com
viable alternative to traditional paper-based laboratory notebooks, labfolder allows scientists to document and organize their research, plan their experiments and collaborate
with others digitally. The software provides an intuitive user interface and is compliant
with the rules of Good Scientific Practice (GxP), including full audit trail and digital
signatures for maximum intellectual property protection. labfolder is also available on
all mobile devices operating under Android and iOS, allowing scientists to access and
manage their data from everywhere. labfolder is free for individual scientists and small
groups and offers advanced functions for large research groups and enterprises for
a monthly fee.
53
Biotech Companies
Labor Berlin – Charité Vivantes
Services GmbHLabor Berlin –
Charité Vivantes GmbH
Labor Berlin Services is the service subsidiary of Europe’s largest hospital laboratory laborberlin.com
for clinical pathology and offers complete solutions for any kind of testing for the ivd
industry, CROs, the pharmaceutical industry, life science companies and research facilities, while Labor Berlin is the exclusive laboratory partner of Charité - Universitätsmedizin Berlin and the Vivantes Network for Health. Labor Berlin and Labor Berlin Services both perform over 35 million analyses in clinical pathology per year and provide
the diagnostic services for approximately 400.000 in-house patients a day and some
one million out-patients per year.
LGC Genomics GmbH
LGC Genomics is the division of LGC with specific expertise in high quality, cut- lgcgenomics.com
ting-edge genomic and related services and products. LGC Genomics delivers:- Next
generation sequencing services- DNA sequencing- Genomics services- Nucleic acid
extraction services- DNA extraction products. LGC is an international science-based
company and market leader in analytical, forensic and diagnostic services and reference standards (lgc.co.uk).
LGC GmbH
Production of calibration substances for purity testing of drugs.
Life Glimmer
Life Glimmer is a customer-oriented consulting and contract research company with lifeglimmer.com
the goal of providing the biotechnological, biomedical and environmental research
communities an efficient way to outsource scientific modeling and computing needs.
Limetec Biotechnologies GmbH
The core competence lies in the development of high-speed and high-quality proof limetec-biotechnologies.de
systems for the detection of pathogens, as well as in the allelic discrimination of hereditary diseases. All products are marked with the CE-Certificate. The second area
of expertise is the creation of communication networks which connect out-patient and
hospital patient treatments, intensify data exchange and provide information to all health
institutions, thus establishing partner relationships between them.
Lipidomix GmbH
LC/MS/MS based high trouput analytic of lipid mediators and metabolites. Analytical lipidomix.de
method development, analytical support for LC/MS/MS in life science, food safety, forensic science.
MagForce AG
MagForce AG is a leading medical technology company focusing on nanomedicine magforce.com
in oncology. The company’s proprietary procedure, NanoTherm® therapy, enables the
targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are
components of the therapy and have received EU-wide regulatory approval as medical
devices for the treatment of brain tumors.
Marinpharm GmbH
Development and marketing of genetically altered cell lines on the basis of new fluores- marinpharm.com
cence markers. Generation of stably transfected fluorescent cell lines.
MedInnovation GmbH
MedInnovation GmbH has developed a new method and a special ESR-analyser, which medinnovation.de
for the first time allows a simple routine laboratory test for evaluation of functional characteristics of plasma proteins and further opens a reliable possibility for cancer diagnostic, named MMS-technology (mobility of molecular structure).
Medipan GmbH
Development, manufacturing and international distribution of radioactive (125J-IRMA) medipan.de
and non-radioactive (Elisa) in vitro-diagnostic tests, covering the field of Autoimmunity,
mainly in Thyroid and Diabetes Typ 1 and automated interpretation of cell-based immunofluorescence tests by the AKLIDES system.
MerLion Pharmaceuticals GmbH
The business purpose of the Company is the research, production, optimization and merlionpharma.com
the development by way of pre-clinical as well as clinical trials of new molecules for the
treatment of infectious diseases.
Merz Pharmaceuticals GmbH /
Standort Potsdam
Merz is one of the leading research-based health care companies. Merz Pharmaceu- merz.de
ticals has achieved a leading position in Alzheimer’s research with the world’s first
drug for the treatment of moderate to severe Alzheimer’s disease. With high quality
products from tetesept® and Merz Spezial®, Merz is making a key contribution to health
and wellbeing.
Metabolomic Discoveries GmbH
Metabolomic Discoveries is an analytical service and research company. We provide metabolomicdiscoveries.
mass spectrometry based metabolite profiling and fingerprinting of biological material, com
as well as single compound measurements.
Metanomics GmbH
Metabolite Profiling for identification of gene function relationship in plants, metabolite metanomics.de
biomarkers and metabolic networks.
Identification of metabolic biomarkers for pharmacology, toxicology, diagnostic and metanomics-health.de
nutrition.
MetrioPharm AG
MetrioPharm AG develops innovative therapies for infectious diseases on the basis of metriopharm.com
new and innovative medicines.
Mfd Diagnostics GmbH
The mfd Diagnostics GmbH (BT Luckenwalde) is a life science research and develop- mfd-diagnostics.com
ment company for diagnostic and therapeutic application of innovative laser technologies. The main advantages of the developed technologies are the non-/minimally-invasive measurement methods, the non-artificial approach and the possibility of real-time
measurement. Therefore, those are promising tools for the diagnosis and therapy monitoring in the neurological practice and in the perinatal surveillance.
54
mikromol.de
Biotech Companies
MicroDiscovery GmbH
MicroDiscovery GmbH is a leading provider of high quality software for biomolecular microdiscovery.de
research, innovative diagnostics and personalised medicine. The company is ISO 9001
certified and has a strong track record in creating software systems in accordance with
relevant regulatory directives for the life science and IVD industry. Customised services
ranging from biostatistical data analysis to bioinformatical design and support of complex research projects complete the product line of MicroDiscovery.
Microparticles GmbH
Development, manufacture, surface modification and characterization of mono-disperse microparticles.de
polymer particles in the nano- and micrometer range. In addition to classic polystyrol
and polyacrylate-based polymer particles, microparticles GmbH has launched new
melamine resin particles on the market with exceptional chemical and physical qualities. The main areas of application are in particle measurement technology, medicine,
biochemistry and microelectronics etc.
Minerva Analytix GmbH
Minerva Analytix GmbH is a leading analytical service lab for the control of microbial minerva-analytix.com
contamination. Our core competence lies in the control of mycoplasma, bacteria and
viruses in cell cultures and biopharmaceuticals
Minerva Biolabs GmbH
Minerva Biolabs develops and produces IVD kits for diagnosing pathogens and for minerva-biolabs.com
contamination control, especially mycoplasma in cell cultures and biopharmaceutical
products. Minerva Biolabs is also active in ensuring water quality with sensitive processes for detecting legionella. Our distributors ensure that our products are available
worldwide, quickly and at a good price.
mivenion GmbH
mivenion is a life-science company founded in Berlin aiming on the development and mivenion.com
commercialization of diagnostic and therapeutic products. The company is built on two
innovative technologies: the fluorescence camera system Xiralite for diagnostic imaging
of early rheumatoid arthritis and a proprietary bioactive polymer drug development
platform. Xiralite is mivenion´s first product on the market.
MLB Mikrobiologisches Labor
GmbH
Accredited test laboratory for drinking water, clean rooms, sterility, bioburdens, D-PL- mikroberlin.de
13398-01-00, EN 17025. Accreditation according to VDI 6022.
Molnar-Institut für angewandte
Chromatographie
Molnar-Institute, established in 1981, offers you a complete scientific and technical molnar-institute.com
service for all problems concerning Quality by Design (QbD) for HPLC-methods. We
develop for you the Design Space for your HPLC-separation and establish Critcal Quality Attributes (CQA’s). We offer detailed DryLab-courses and show you, how to develop
robust methods in the Design Space and how to save time. We supply and implement
the DryLab-software and train your coworkers. We assist you in automated method
development processes and support you in the selection of proper instruments, their
installation and use.
MOLOGEN AG
MOLOGEN AG is a biopharmaceutical company based in Berlin and specializes in mologen.com
the development of novel DNA-based medicines against cancer and vaccines against
infectious diseases. The proprietary platform technologies MIDGE® and dSLIM® build
the foundation for all business activities. The company was founded 1998 and was one
of the first biotechnology companies to go public.
moloX GmbH
moloX GmbH is a company focusing on custom protein production in bacterial and in- molox.de
sect cell expression systems and subsequent protein purification to ultra-high purity. On
customer demand a team of experts can perform protein crystallization experiments
and determine the 3D structure of target proteins by X-ray crystallography.
MRI.TOOLS GmbH
MRI.TOOLS´s main focus is the development, sales and services of innovative hard- mritools.de
ware and novel technology for magnetic resonance imaging (MRI), computed tomography (CT) and positron emission tomography (PET). Our product portfolio encompasses
enabling radiofrequency (RF) coils tailored for a broad range of applications, devices
designed for reliable cardiac gating of imaging plus accessories that will make your
daily life more comfortable. MRI.TOOLS is also very proud to offer consulting services
such as validation and certification of medical devices.
Myelo Therapeutics
Myelo Therapeutics GmbH develops innovative treatments in areas of high unmet med- myelotherapeutics.com
ical needs.
Nano Access Technologies Ltd.
The company addresses the combined access to key technologies such as life science nano-access.com
and nanotechnology. As a first product, a low cost AFM for operation with so-called active cantilevers has been developed. Besides this, functionalized cantilevers for future
biosensors are another focus of the company.
Nanolytics Gesellschaft für
Kolloidanalytik mbH
We are a contract laboratory specializing in the physico-chemical characterization nanolytics.de
of pharmaceutical proteins, biopolymers, nanoparticles and colloidal systems. Our
core-competences are Analytical Ultracentrifugation, in combination with Static and
Dynamic Light Scattering as well as spectroscopic (CD, fluorescence) and thermodynamic techniques (ITC, DSC).
Nanopartica GmbH
Nanopartica GmbH optimizes existing products of other companies, but are also devel- nanopartica.com
oping new products and materials. In particular, companies in surface-, bio-, and medical-technology can benefit from nanopartica. By means of functionalized polymers, we
can encapsulate guest molecules (drugs, dyes, vitamins), particles (gold, silver, platinum), or ions. This will indirectly change the guests properties and expands its scope.
55
Biotech Companies
nanoPET Pharma GmbH
As a technology and service provider to the biopharmaceutical industry nanoPET fo- nanopet-pharma.com
cuses on the R&D, production as well as marketing of innovative drug substances for
diagnostic imaging based on novel nanoparticular materials. nanoPET offers consulting
and contract research services, preclinical contrast agents (MRT, CT, US, NIR, PET) as
catalog items and pursues the preclinical development of its patented core technology
of inorganic nanoparticle PET tracers.
NovaBiotec® Dr. Fechter GmbH
Microbiological and chemical investigations, in particular of soil, water and air samples, novabiotec.de
planning / inspection of sanitation, in particular analytics and sanitation support for
mould and dry rot, incl. education in this field. Delivery of production auxilliaries and
support for biogas plants with biological treatment processes incl. application, insulation and preservation of enzymes. Research, development and marketing of test kits
for breweries and malthouses.
NOXXON Pharma AG
NOXXON Pharma is a biopharmaceutical company pioneering the development of noxxon.com
a new class of proprietary therapeutics called Spiegelmers. Spiegelmers are the
chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a
diversified portfolio of clinical stage Spiegelmer therapeutics: Spiegelmer® NOX-E36,
Spiegelmer® NOX-A12, Spiegelmer® NOX-H94. The Spiegelmer platform provides the
Company with powerful and unique discovery capabilities, which have generated a
number of additional leads under preclinical investigation. Located in Berlin, Germany,
NOXXON is a well financed mature biotech company with a strong syndicate of international investors, approx. 60 employees and a highly experienced management team.
OakLabs GmbH
OakLabs provides the most flexible products and services for large scale custom SNP oak-labs.com
genotyping on the market. OakLabs offers several formats for analysing a variable number of SNPs in any sequenced organism.
OctreoPharm Sciences GmbH
OctreoPharm Sciences GmbH is a clinical development company focusing on diagnos- octreopharmsciences.com
tic radiopharmaceuticals.
Omeicos Therapeutics GmbH
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing omeicos.com
a new Mode of Action for the treatment and prevention of atrial fibrillation. OMEICOS'
novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective
signaling pathway that not only stabilizes the heart rhythm but shall provide curative
effects to the diseased organ by preventing its electrical and structural remodeling.
OpTricon
Entwicklungsgesellschaft für
optische Technologien mbH
OpTricon develops and produces mobile readers for quantitative analyzes of Immuno- optricon.de
assays for Point-of-Care-diagnostics, especially Lateral Flow Assays (LFA). Additional
business segments are components and Systems for signal transmission and sensors
for lbioanalytics. opTricon develops the devices in partnership with the customers
and works as OEM-suppliers and is certified by TÜV Rheinland according EN ISO
13485:2003+AC: 2007 and EN ISO 9001:2008.
ORGANOBALANCE GmbH
ORGANOBALANCE is a company specializing in microbial strain development and organobalance.com
screening. As a R&D contractor ORGANOBALANCE develops new biological products
in the areas of nutrition, personal care and health care. The company draws on its own
collection of microbial strains suitable for food applications and its OASSYS® bioassay
systems. In the field of “metabolic engineering” ORGANOBALANCE exploits Saccharomyces cerevisiae yeast for synthesis of substances for the industrial and pharmaceutical industry.
ORGANOBALANCE Medical AG
ORGANOBALANCE Medical AG funds and promotes the research and development organobalancemedical.com
of novel therapies based on specific probiotic cultures, aiming to develop active substances and mechanisms for innovative medicinal products and medical devices, as
well as offer new therapeutic concepts for hitherto inadequately treatable indications.
ovalehn GmbH
Production and application of specific recipes -containing IgY for diagnostics and oral, ovalehn.de
passive immune therapy.
Pentracor GmbH
In the case of cardiac infarction, C-reactive protein (CRP) results in an increase of the pentracor.com
primary damage. Based on a new prototype, the company Pentracor GmbH aims to
develop an adsorber for therapeutic reduction of CRP, lead it to approval, establish its
certified production and market the product after clinical validation.
Peptides&elephants GmbH
Custom synthesis of peptides and peptide libraries Development parallel Synthesis peptides.de
technologies Distributor of Peptide Synthesis Automation.
PharmaSol GmbH
Modification of ingredients or introduction of new metabolic pathways in plants with pharmasol-berlin.de
gene-technology methods.
PlasmaChem GmbH
PlasmaChem GmbH is an innovative R&D and manufacturing company specializing in plasmachem.com
nanomaterials, plasma- and ultra-thin film technologies. The company manufactures
nano-coated medical implants (stents), nanomaterials, additives for metal plating (applied e.g. by Siemens AG), new additives to engine oils on the base of nanodiamonds
and other industrial nanoproducts.
56
Biotech Companies
PolyAn, Gesellschaft zur
Herstellung von Polymeren für
spezielle Anwendungen und
Analytik mbH
PolyAn is specialised in Molecular Surface Engineering (MSE). Using our surface modi- poly-an.de
fication expertise PolyAn optimises the performance of analytical systems by improving
the signal-to-noise ratio as well as the reproducibility of consumables for multiplex diagnostics, LifeScience research and screening applications. PolyAn?s product portfolio
includes functionalised microarray slides, microparticles for multiplex bead arrays and
functionalised membranes for medical diagnostic applications.
Preclinics Gesellschaft für
präklinische Forschung mbH
Preclinics is a commercial cooperation partner for preclinical research and develop- preclinics.com
ment. As a competent, creative and experienced partner preclinics investigates pharmaceutical substances, therapeutic methods and proceedings as well as medical
products during the preclinical phase. Additional we provide custom antibody production in llama, goat, sheep, rabbit and other species.
Predemtec GmbH
Predemtec GmbH is a company focused on the research, development and manu- predemtecDX.com
facture of innovative diagnostic tests for use in the detection of dementia-related risk
factors. The goal has been to make the early and reliable diagnosis of various dementia-related illnesses a reality through the use of our innovative diagnostics tests.
ProBioData GmbH
BioProcessDB is a database solution for bioprocess R&D. It's designed to become the probiodata.de
linking tool in your information process and to integrate the data i. e. from the SCADA
system, the sample data management and the strain management.
ProBioGen AG
ProBioGen is a Contract Development and Manufacturing Organization (CDMO) and probiogen.de
Technology Provider, with extensive expertise in cell line engineering, process development (upstream- and downstream process) and GMP manufacturing of biopharmaceuticals. Offering state-of-the-art contract development and manufacturing services
as well as access to proprietary cell lines (AGE1.cell lines®) for the manufacturing of
biopharmaceuticals and vaccines. The company possesses the manufacturing authorization from the competent authority and meets the quality standards required by the
EMA and the FDA guidelines.
ProteaImmun GmbH
ProteaImmun is a specialized proteomic company providing purified human proteins, proteaimmun.net
antibodies and ELISAs. Our proteins are designed for structural and functional studies of proteases screening and evaluation of protease inhibitors and modulators. Furthermore we develop highly sensitive ELISA kits and antibodies. Our Focus: MMPs,
ADAMTs, HtrAs. ProteaImmun produces a unique range of recombinant proteases for
medical and pharmaceutical research. The main focus is on human Matrix Metalloproteases (MMPs), ADAMTS and HtrA proteins which play an important role in neurodegenerative disease, ancer and arthritis. Customer Service: ProteaImmun provides
activity analysis by zymography adapted for MMPs.
PROTEKUM - Umweltinstitut
GmbH, Oranienburg
We plan to eliminated fluid und solid waste products in a manner which is compatible protekum.de
with environment protection. Our methodology is largely based on painstaking analysis.
We use modern equipment and scientific methods. Protekum offers high-quality products and services in environmental analysis redevelopment.
Proteome Factory AG
Biomarker & target discovery, validation, analysis of food and ingredients, absolute proteomefactory.com
quantification of proteins and peptides, sequencing and characterization of proteins
and antibodies (CDR), 2DE and LC-MS based proteomics studies, pharmacokinetics,
pharmaco, immuno and membrane proteomics, protein identification, characterization
of proteins and peptides (PTMs, e.g. phosphorylation, glycosilation), quality control,
mass determination, N-terminal amino acid sequencing, silver staining kit etc.
Provitro GmbH
Provitro combines more than ten years of experiences in commercialisation of cell provitro.de
culture technologies, Tissue Microarrays and immunohistochemical analyses with the
scientific expertise of the Pathological Institute of the Charité, Berlin. Based on a quality
management system according to ISO 9001:2008, we provide our customers not only
with high-quality products, CE marked in vitro-diagnostics and state-of-the-art services
but also with individual solutions for their specific requests.
Rapidozym Gesellschaft
für Laborhandel und DNA
Diagnostika mbH
Expertise of cell biologists cell manufacturing and clean room technology specialists. rapidozym.de
Focuses on clinical stem cell product development portfolio are stroke, myocardial infarction and plastic surgery.
RENESA UG
(haftungsbeschränkt)
Manufacturing and distribution of rapid tests, mainly for medical purposes (Point of renesa.de
Care Testing).
RiNA GmbH
RiNA has developed systems for cell-free protein biosynthesis based on pro- and eu- rina-gmbh.eu
karyotic cell lysates. A synthesis service is realised in RiNA’s own laboratories and
complements the EasyXpress Kits (Qiagen). The purchase of Roche´s RTS-products
enables RiNA now to be a key player in the field of cellfree biosynthesis with a large
variety of products. Another research focus is the development of aptamers (DNA and
RNA) for biosensors.
RIPAC-LABOR GmbH
RIPAC-LABOR offers high-quality diagnoses of bacterial infections, particularly in poul- ripac-labor.de
try, pigs and cattle, but also in other farm and domestic animals. The company uses
pathogen differentiation to provide quick and effective methods for fighting pathogens.
It performs resistance tests and epidemiological analyses and also focuses on producing herd-specific vaccines.
Roboklon GmbH
Distribution, Marketing and Development of Products for Molecular Biological Research roboklon.de
and Genetic Engineering.
57
Biotech Companies
ROVALAB GmbH
Our Master Mixes for QPCR, Standard-, Hot Start- and High Fidelity PCR as well as our rovalab.com
high quality critical raw materials and reagents such as DNA Polymerases and dNTPs
are designed to help you successfully and rapidly solve your scientific and manufacturing tasks.
Royal Biotech GmbH
Royal focuses on developing, manufacturing and marketing innovative kits, portable royalbiotech.com
or micro-structured systems, and the next generation of diagnostic chips for near real-time environmental, food safety, disease and laboratory diagnostics.
Scienion AG
Scienion is a life science company in the markets of dispensing systems and microar- scienion.de
ray technologies. The product portfolio comprises hardware, consumables and services. Scienion’s leading product is the sciFLEXARRAYER dispensing system, available
in a product line of six size versions. The dispenser allows the aspiration of ultra low
liquid volumes from different reservoirs and non-contact micro drop delivery in the
picoliter to microliter range onto a variety of carriers.
Sepiatec GmbH
Production, development and sales of automated HPLC machines for high-throughput sepiatec.com
purification and fractioning of complex substance compounds.
Seramun Diagnostica GmbH
Seramun offers peptide synthesis, purification and conjugation of proteins, production seramun.com
of antibodies, customer research, in vitro-Diagnostics. We focus on the development
and production of enzyme immunoassays for diagnosis of viral and bacterial infections
and autoimmune diseases of the gastrointestinal tract, the development of multi-parameter assays as microtitre plate assays and as membrane immunoassays, as well as
development of ready-to-use substrate solutions and for protein stabilizers.
SGS INSTITUT FRESENIUS
Berlin GmbH & Co. KG
Analytical laboratory services and consulting for development, production and quality institut-fresenius.de
control of drugs.
SIFIN Institut für Immunpräparate Development, production and purification of monoclonal antibodies for use in diag- sifin.de
nostics. Development and production of blood grouping reagents, Serafol® bedside
und Nährmedien GmbH Berlin
cards and test reagents for serotyping of Salmonellae, Shigellae, E. coli and Yersiniae.
Development and production of culture media for microbiological diagnosis.
Signature Diagnostics AG
Signature Diagnostics is dedicated to the discovery, validation and commercial de- signature-diagnostics.de
velopment of novel diagnostic products that predict outcome and drug response in
patients with colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and ovarian
cancer. Signature believes that patient selection and stratification based on molecular
gene signatures will soon become an important component of routine cancer treatment.
Silence Therapeutics AG
Silence Therapeutics AG is a leading RNAi therapeutics development company and silence-therapeutics.com
offers a novel, proprietary siRNA technology (AtuRNAi) and proprietary systemic delivery systems for siRNA (AtuPLEX, DACC and DBTC). SILENCE pipeline consists of
both partnered and internal programs of which 3 clinical phase II and 1 clinical phase
I programs are partnered with Pfizer/Quark (2 ophthalmic indications) and Novartis/
Quark (2 kidney indications). Silence?s internal lead compound Atu027 is currently in a
Phase I clinical study for the treatment of solid tumours.
SINA Science Services GmbH
SINA is a modern company providing elaborate services in molecular biology and sina-science-services.de
protein biochemistry. Together with our industrial partners and customers from research institutions we develop complex cloning and mutagenesis strategies including
high-throughput applications. We offer cloning of genes, expression and purification of
proteins, DNA and RNA isolation from numerous biological materials and the production
of competent cells with high transformation efficiency.
SLM- Speziallabor für
Microbiological quality control for medical devices, pharmaceuticals, cosmetics, drink- speziallabor.com
angewandte Mikrobiologie GmbH ing water, foodstuff, monitoring in clean rooms.
Sopat GmbH
SOPAT is specialized in the analysis of particulate systems. The company develops and sopat.de
markets an innovative particle measurement technology for real-time analysis of multiphase systems. Particles, such as droplets, grains, cells or bubbles, are measured with
high precision in running processes.
STRATEC Molecular GmbH
STRATEC Molecular GmbH is a globally active provider of innovative system solutions invitek.de
for nucleic acid sample collection, stabilization, and both manual and automated purification from any sample type. Since 1992 the company is internationally respected for
its outstanding and high performance technology platforms and offers a broad spectrum of superior products for molecular diagnostics, drug discovery and Life Science
research.
Strix Diagnostics GmbH
Strix Diagnostics is a medical diagnostics company specializing in customized devel- strix-diagnostics.de
opment of certified analytical systems for multiparameter in vitro-diagnostics.
Surflay Nanotec GmbH
Surflay Nanotec GmbH, a spin-off company from Capsulution NanoScience AG, is spe- surflay.com
cialized on coating colloidal and planar materials with functional films. Key technology is
the patented LbL-Technology® with polymers. Applications are in the fields of separation materials, pigment encapsulation, bio-sensing and diagnostic particles. In addition
to customer tailored projects Surflay offers an unique range of products of tunable
multifunctional nano-or microparticles and dye-labeled polymers.
58
Biotech Companies
t-cell Europe GmbH
t-cell Europe GmbH, a spin-off of the Berlin Brandenburg Center for Regenerative Med- t-cell.de
icines (BCRT), is aiming to become the world’s technology leader in the application
of T-cell-based therapies used in transplantation medicine. Over the next few years,
with its three proprietary platform technologies, the company will develop and clinically
validate novel T-cell-based products and corresponding diagnostics to regulate the
immune system and treat viral infections. The company’s lead reference product will
be a first-in-class Treg cell product/therapy for kidney transplantation that suppresses
organ rejection in recipients
Thanares GmbH
Development, use and marketing of analytical process for diagnostic and therapeu- thanares.com
tic purposes. Future business activities: detection process for bioactive substances in
bodily fluids, isolation, characterization and investigation of bioactive compounds from
plants, in particular insoluble proteins or low concentrations of proteins, development
of low cost genetic systems for over-expression and/or production of such proteins.
TheraKine BioDelivery GmbH
Development of antibody drug delivery systems and related tasks.
Thermo Fisher Scientific –
B·R·A·H·M·S GmbH
Thermo Scientific Biomarkers (B·R·A·H·M·S GmbH) explores, develops and produces thermoscientific.com/
new diagnostic test procedures to improve the diagnosis, and thereby the treatment, of brahms
life-threatening illnesses. This takes place with over 470 employees, in the disease areas infectiology, cardiology and pneumology as well as thyroid, autoimmunity and cardiology on the basis of our own patented biomarkers. Since October 2009 B·R·A·H·M·S
GmbH is part of Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving
science.
TIB MOLBIOL Syntheselabor
GmbH
In 1990, TIB MOLBIOL became the first German manufacturer of oligonucleotides. In tib-molbiol.com
addition to designing and synthesizing primers and probes for Real-Time PCR assays,
we develop and produce LightMix® Kits for Roche Diagnostics LightCycler® Instruments,
covering applications in Clinical Chemistry, Pharmacogenetics, Pathogen Detection, as
well as Cancer Research. TIB MOLBIOL is ISO 13485 and ISO 9001 certified.
TissUse GmbH
TissUse is a vibrant growth company providing high-value services in the area of tissue tissuse.com
culture analysis of drug candidates, cosmetics, chemicals and consumer products.
therakine.com
TransTissue Technologies GmbH TransTissue has been a subsidiary of BioTissue Technologies, Freiburg since Septem- transtissue.com
ber 2001. With more than 15 years of experience in regenerative medicine, the scientists of TransTissue Technologies have developed second-generation autologous tissue
replacements, e.g. cartilage and bone grafts. We are mainly concerned with inventions
and the development of tissue engineering products for regenerative medicine. We
offer a broad panel of services in the field of regenerative medicine.
UGA Biopharma GmbH
UGA Biopharma a private Research and Development company, focuses on Research, ugabiopharma.com
Development and Commercialization of Biopharmaceutical products under contract
with other Biopharmaceutical companies. UGA Biopharma conducts power of biosciences to develop high-tech, last generation of biomedicine, diagnostic kits, molecular
biology items and also offers world class services in biotechnology area.
Umwelttechnik-Berlin UG
Feasibility studies, development, planning, construction and operation of biotechno- bartetzko.com
logical plants for groundwater, process water and waste water purification. Accredited
microbiological laboratory for the investigation of drinking water, groundwater, bath
water, soils, food, anti-microbial active ingredients and sterility according to Ph.Eur,
approved in accordance with BiostoffV and the German infection protection act (Infektionsschutzgesetz).
Zellwerk GmbH
Zellwerk produces the proprietary Z® RP cell cultivation system, comprising rotating zellwerk.biz
bed bioreactor, GMP Breeder, Control Unit, software. Bioreactors with 50-5000 ml volume, 0,2-2 m² seeding surface, different cell carriers, can be delivered. In this culturing
system cells grow tissue-like, being embedded in self-generated extra-cellular matrix.
The technology opens unique opportunities for the GMP-compliant expansion of stem
cells and primary cells, manufacturing of cell-seeded implants as well as production
of recombinant proteins. In addition, we have recently developed a new bioreactor for
expansion of immune cells for cell therapy of leukemia and several types of cancer.
Zentrum für molekulare
Onkologie GmbH
Innovative methods for diagnostic and therapy of tumor diseases - Molecular genetics molekulare-onkologie.eu
(K-RAS, PCA3, Septin9, ...) - Chemoresistance assay for prediction of chemotherapy Pathology Development of new biomarkers and analytical services for studies.
Zytomed Systems GmbH
Zytomed Systems´ focus is the development, production and distribution of antibod- zytomed-systems.de
ies and detection systems for immunohistochemical cancer diagnostics as well as reagents and kits for in-situ hybridisation.
59
BioTOP is a joint initiative of the state of Berlin and the state of Brandenburg under the umbrella of the Berlin Partner für Wirtschaft und Technologie GmbH and takes part in the
Cluster Management HealthCapital. BioTOP is funded by the federal state of Berlin, the federal state of Brandenburg and the Investitionsbank Berlin, co-funded by the European
Union (European Fund for Regional Development). Investing in your Future

BioTOP-Report 2014 - Berlin Business Location Center

Transcription

Similar documents

Korrosion in Heiz

4 Verzeichnis Fernsehen

On the road to a dependable new economy Auf dem

Uebersichtsarbeit zu CROs in Deutschland

Flyer Update Ernährungsmedizin - ZIEL